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Abstract 
According to UNAIDS, there are ~36.9 million people infected with HIV-1 in the world. 
Of those, 25.8 million live in sub-Saharan Africa and 6.8 million in South Africa. HIV-1 
subtype C accounts for over 95% of HIV infections in South Africa. HIV-1 retrovirus 
acquires mutations rapidly because of the viral reverse transcriptase. Naturally 
occurring polymorphisms distinguishing wild type C-SA PR from other proteases make 
it less susceptible to inhibitors. E35D↑G↑S is a C-SA PR variant with a double insertion 
in the flap region of the protease. The insertions and background mutations may 
decrease susceptibility to inhibitors as well as alter kinetic parameters due to increased 
flap flexibility. This study intended to characterise the effect of the mutations and 
insertions in E35D↑G↑S on structural, kinetic activity and drug susceptibility. 
Chemically-synthesised E35D↑G↑S autocatalyses rapidly, impeding further 
characterisation. There was no detectable overexpression of the E35D↑G↑S protease in 
Escherichia coli BL21 (DE3)pLysS and Rosetta 2
® 
cells. If the protease is catalytically 
enhanced, attributed cytotoxicity may prevent overexpression of the protein. Increased 
autocatalytic activity could also prevent crystallisation. Inactive E35D↑G↑S D25A did 
not overexpress either, indicating that codon harmonisation with the expression host 
ought to be performed.  C-SA PR was shown to be a predominantly beta-sheeted 
protein using circular dichroism spectroscopy. The KM of the fluorogenic substrate 
resembling the capsid/ p2 cleavage site for C-SA PR was 22.02 ±4.09 µM. The specific 
activity, catalytic turnover and catalytic efficiency of the wild-type C-SA PR protease 
were found to be 35.68 ±1.06 µmole.min
-1
.mg
-1
, 12.79 ±0.38 s
-1
 and 1.17 ±0.055 s
-1
.μM-1, 
respectively. The thermodynamics of binding of atazanavir, ritonavir and darunavir to 
C-SA PR were determined using isothermal titration calorimetry. The binding of 
atazanavir and ritonavir to C-SA PR is entropically driven and enthalpically opposed. 
However, the binding of darunavir to C-SA PR was found to be both entropically and 
enthalpically favourable. The dissociation constants of the inhibitors in the absence of 
substrate (Kd) are in the pico-molar range and increased by approximately one order of 
magnitude when saturating concentrations of substrate were introduced. Atazanavir, 
ritonavir and darunavir have dissociation constants (Kd) of 160.56 ±54.59 pM, 113.34 
±46.47 pM and 10.24 ±6.02 pM, respectively. Darunavir binds significantly tighter.  
Keywords: C-SA PR, E35D↑G↑S, insertion mutations, protease, autocatalysis, ITC.  
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1. Introduction 
1.1 Discovery and identification of HIV as the causative agent of AIDS  
The term acquired immunodeficiency syndrome (AIDS) was introduced on the 27
th
 of July 
1982 based on the nature of the illness. It was then accepted that AIDS did not discriminate 
between race, gender and sexual orientation (Marx, 1982). One year later, Luc Montagnier 
and associated researchers at the Pasteur Institute in France isolated the first strain of the 
human immunodeficiency virus (HIV) (Bare-Sinoussi et al., 1983). In 1984, HIV was 
undoubtedly proven to be the causative agent of AIDS by Robert Gallo’s group (Safai et al., 
1984). However, the virus itself was termed HIV in 1986; before that, the virus variants were 
classified under a different taxonomy (Coffin et al., 1986
1
;
 
Coffin et al, 1986
2
). 
1.2 Taxonomic classification of HIV 
The HIV species belongs to the Lentivirius genus of the Orthoretrovirinae subfamily that is 
encompassed in the Retroviridae family (International Committee on Taxonomy of Viruses: 
http://ictvonline.org/virusTaxonomy.asp accessed on 22
nd
 January 2015). There are 
contradicting hypotheses regarding the emergence of both types of HIV (HIV-1 and HIV-2) 
(Sharp et al., 2006). Nevertheless, it is accepted that HIV-2 originates from the simian 
immunodeficiency virus (SIV) that infects the sooty mangabey and, the more virulent HIV-1, 
originates from the SIV that infects chimpanzees (Sharp et al., 2001; Keele et al., 2006, 
Sharp and Hahn, 2011). It is speculated that the virus initially infected a human host via 
ingestion of SIV positive chimpanzee meat. However, the exact origin of HIV is uncertain 
(Fauci, 2003). 
1.3 HIV-1 variants 
HIV-1 is divided amongst groups M, N, O and P according to the most common recent 
ancestor of each group (Tebit and Arts, 2011). Most of the infections with HIV are due to the 
constituent subtypes of group M. There are nine subtypes making up group M; those are: A, 
B, C, D, F, G, H, J and K. There are also circulating recombinant forms (CRFs) that emerge 
due to the recombination of viruses of different subtypes within hosts infected with multiple 
subtypes. Additionally, there are significant primary-structure differences between variants 
that belong within each subtype (Hemelaar et al., 2006; Hemelaar, 2012). 
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1.4 Estimates of HIV infections 
The most recent estimate made by UNAIDS was in 2014 and it revealed that the number of 
people infected with HIV in the world is peaking at 36.9 million (UNAIDS, 2015; 
http://www.unaids.org/en/resources/documents/2015/HIV_estimates_with_uncertainty_boun
ds_10-2014 , last updated on 12
th
 August 2015, accessed on 11
th
 October 2015). UNAIDS re-
estimates HIV populations each year using updated modules and new assumptions (personal 
communication with the aidsinfo team from UNAIDS). Thus, trailing research publications 
that present estimates over the years, gives the impression that the number of HIV-infected 
patients is decreasing. On the contrary, the number of HIV infected people in the world 
displays a rising trend (UNAIDS, 2015). However, the infection rate has decreased (Weiss, 
2008). Nevertheless, sub-Saharan Africa is currently a hotspot for the transmission of HIV 
(UNAIDS, 2015). 
Sub-Saharan Africa is home to 25.8 million people infected with HIV and 6.8 million of 
those people reside in South Africa (UNAIDS, 2015). In a study done by Hemelaar, 2012, it 
was shown that HIV-1 subtype C is the most common of the subtypes, accounting for 48% of 
the global infections and for over 95% of the infections in the South African region 
(Hemelaar, 2012; UNAIDS 2015). 
1.5 General physiology of HIV-1 
The mature HIV retrovirus encloses two identical, positive-sense, single strands of RNA 
which dimerise. Each of the ~9 kb RNA strands encodes the full viral genome (Frankel & 
Young, 1998; Ahlquist et al., 2003; Takahashi et al., 2000). The viral RNA is reverse 
transcribed into dsDNA by the reverse transcriptase (RT) of the virus (Frankel & Young, 
1998). It is the process of reverse transcription that notoriously creates numerous variations in 
the viral proteins that lead to altered drug susceptibility. This is because the viral reverse 
transcriptase (RT) does not have proofreading capabilities. As such, the enzyme is ten times 
less accurate than other viral polymerases (Roberts, 1988) 
The viral RNA has an upstream promoter located in the 5' long terminal repeat (LTR) which 
is recognised by the viral protein Tat (trans-activator of transcription). Tat increases the rate 
of transcription of the viral genome and is also essential in the translation of the viral proteins 
(Jeang et al., 1999; Kao et al., 1987). The transport of RNA is assisted by the lentivirus 
protein R (Vpr) while the regulator of expression of virion proteins (Rev) coordinate 
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variations in the splicing of RNA so that the different viral proteins may be produced 
(Frankel & Young, 1998; Freed, 1998; Schubert & McClure, 2005; Terwilliger et al., 1989). 
The viral genome translates into 15 proteins, three of which are enzymes (Figure 1 A and B) 
(Frankel & Young, 1998). The Gag polyprotein chain contains structural proteins such as the 
matrix protein (MA), capsid protein (CA), nucleocapsid protein (NC) and the structural 
proteins p1, p2 and p6 which provide structural support for the polyprotein chain. The Pol 
polyprotein chain contains the three enzymes: reverse transcriptase (RT), integrase (IN) and 
protease (PR). The envelope polyprotein (Env) consists of the surface protein gp120 (SU) and 
the transmembrane protein gp41 (TM). The viral protein U (Vpu) overlaps with Env at the 5' 
end and is translated from a different frame (Hout et al., 2004).  The virion infectivity factor 
(Vif), Vpr, Tat, Rev and the negative regulatory factor (Nef) are spliced out independently 
(Bogerd et al., 2004; Frankel & Young, 1998; Freed, 1998; Niederman et al., 1989; 
Terwilliger et al., 1989). 
The Env proteins; namely SU and TM are synthesised at an earlier stage than the rest of the 
viral proteins, within the endoplasmic reticulum (ER) of the host cell (Freed, 1998). Nef 
down-regulates surface CD4 after Env binding and viral entry, and Vpu degrades intracellular 
CD4 to prevent newly formed Env from binding to CD4 (Frankel & Young, 1998; 
Terwilliger et al., 1989). The Env proteins are then embedded into the host plasma membrane 
via the secretory pathway (Freed, 1998). The envelope proteins, SU and TM are linked in a 
non-covalent manner after proteolytic cleavage by cellular proteases (Binley et al., 2002). 
Ultimately, proteolytic maturation of the virus is completed after the budding of the virus 
(Richman, 2001). However, it is the virion infectivity factor that inhibits the human host 
defence factor APOBEC3G, thus, preventing detrimental viral hypermutation and ensuring 
the budding of infectious viral particles (Land et al., 2008; Bogerd et al., 2004). 
1.6 HIV – host membrane fusion 
The SU protein recognises the host cell CD4 receptor and binds it. The chemokine co-
receptors, CCR5 and CXCR4, may both interact with the viral SU, thus, SU and the host 
receptors/ co-receptors facilitate the attachment of the virus to the host (Freed, 1998; Colman 
et al., 2003). However, it is the TM protein that brings together and fuses the viral membrane 
with the host membrane after attachment (Figure 2) (Freed, 1998; Colman et al., 2003, 
Teixeira et al., 2011). 
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Figure 1: (A) Organisation of the HIV-1 genome and (B) schematic representation of 
the structure of HIV-1. 
HIV-1 contains the matrix, capsid, p2, nucleocapsid, p1, p6, protease, reverse transcriptase 
including the RNAse H domain, integrase, Vif, Vpr, Vpu, Env proteins (SU and TM), Tat, 
Rev and Nef. Adapted from Freed, 1988. 
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Figure 2: Fusion of the viral membrane with the host cell membrane 
(A) The surface protein gp120 (SU), attaches to the CD4 receptor and the co-receptor(s) 
which may be CXCR4 or CCR5. (B) The transmembrane protein gp41 (TM) folds out and 
implants itself in the membrane. (C) The membranes are either brought together by a TM 
intermediate formation or by a direct mechanism which is not fully understood. However, it 
may well exist, in which case, step D does not occur, but only step E where the membranes 
have fused by a more direct mechanism. However, it is common that the structural 
conformation of TM is radically modified for the fusion of membranes to occur (Teixeira et 
al., 2011). Adapted from Colman et al., 2003. 
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1.7 The life-cycle of HIV-1 
After the viral – host membrane fusion, the matrix proteins dissipate quickly inside the host 
cell to release the viral core formed by numerous capsid proteins. In turn, the CA proteins 
scatter rapidly to release the viral RNA and the encapsulated enzymes RT, IN and PR as well 
as the multiple proteins necessary for the life-cycle of the virus (Frankel & Young, 1998). 
The MA and CA proteins are structural proteins that also assist in the intra-host transport of 
the viral RNA and enzymes. Moreover, the MA and CA proteins assist in the budding of the 
viral particles (Frankel & Young, 1998).  
The three virally encoded enzymes RT, IN and PR are at the epicentre of the HIV life-cycle 
(Figure 3). Subsequent to the release of the three enzymes, 12 proteins and RNA into the 
cytoplasm of the host, the ssRNA is reverse transcribed by RT into ssDNA. The degradation 
of the ssDNA is prevented by the Vif protein. The ssDNA is duplexed by the polymerase 
ability of the RT while the RNAse H domain of the RT degrades the genomic RNA of the 
virus (Beilhartz and Götte, 2010). The dsDNA is transported to the nucleus where it is 
integrated into the DNA of the host by the viral IN. Once integrated, the viral genome 
(known as provirus when integrated) is transcribed by the host cell RNA polymerase II (RNA 
pol II). The transcribed provirus is then spliced and translated for the production of the early 
viral proteins such as the Env proteins and the polyprotein chains, Gag and Pol. These 
proteins are subsequently encapsulated in the budding virus alongside the two RNA 
molecules encoding the viral genome. The encapsulation of the polyproteins is assisted by 
Vpr. Furthermore, the encapsulation of the RNA is driven by the NC present in the 
polyprotein chains. During and after budding of the virus, the viral particles become infective 
once proteolytic maturation is fully performed by the PR.  
Proteolytic maturation involves the cleavage of the polyprotein chains so that functional viral 
proteins can fold and assemble inside the virus so that the virus may become infective 
(Frankel & Young, 1998; Freed, 1998). Before the viral PR can perform the maturation 
function of the viral particles, the PR monomers have to dimerise. First, two Pol polyprotein 
chains align next to one another to dimerise, forming a functional protease which auto-
processes from the polyprotein chain. The protease then cleaves the rest of the polyprotein 
chains into the functional proteins necessary for viral maturation (Louis et al., 1994). 
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Figure 3: The life-cycle of HIV-1  
The virus fuses with the host releasing the viral core which unpacks to liberate the viral RNA, 
enzymes and proteins. The ssRNA is converted to dsDNA by RT. The dsDNA is integrated 
into the host genome by IN. The provirus is transcribed and translated. The translated 
proteins assemble and are proteolytically cleaved for viral maturation as soon as budding 
occurs. Adapted from Teixeira et al., 2011. 
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The enzymes and proteins of HIV-1, including, RT, IN and PR are critical to the life-cycle of 
the virus. Antiretroviral therapy (ART) exploits this phenomenon (Frankel & Young, 1998; 
Freed, 1998; Vella et al., 2012).  
1.8 Current therapy for AIDS 
Since the discovery of HIV, there have been many advances made to deal with HIV and the 
chronic onset of AIDS. Antiretroviral therapy involves the administration of a combination of 
at least three antiretroviral drugs from at least two drug classes (FDA – Approved HIV 
Medicines: http://aidsinfo.nih.gov/education-materials/fact-sheets/21/58/fda-approved-hiv-
medicines# last updated and reviewed on 12
th
 October 2014; accessed on 3
rd
 February 2015).  
Currently there are twenty-five antiretroviral inhibitors approved by the Food and Drug 
Administration (FDA) to be used in antiretroviral therapy. These are distributed amongst the 
following drug classes: nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside 
reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), fusion inhibitors, entry 
inhibitors and integrase inhibitors. In addition, the FDA has approved the use of a 
pharmacokinetic enhancer to assist therapy. Antiretroviral therapy is also referred to as highly 
active antiretroviral therapy (HAART) (World Health Organisation – Antiretroviral therapy: 
http://www.who.int/topics/antiretroviral_therapy/en/. accessed on 9
th
 February 2016).  
1.9 HIV-1 South African subtype C protease (C-SA PR) and protease inhibitors 
Central to this project is the HIV-1 South African subtype C protease (C-SA PR) and a 
double insertion variant of the protease. C-SA PR, like all HIV proteases, is a homodimer. 
Each monomer consists of 99 amino acids and has a subunit molecular mass of 10754.8 Da 
(~11 kDa). The isoelectric point of the protein is 9.32 (Naicker, 2013; Mosebi, 2008; 
Gasteiger et al., 2005). The secondary structure of the protease consists of 48% β-sheets, 4% 
α-helices and 48% random coils. The enzyme folds into a globular protein (Naicker, 2013; 
PDB ID: 3U71). The enzyme is an aspartic protease (EC 3.4.23.16) which has a conserved 
catalytic triad: Asp25, Thr26 and Gly27. Asp25 is the catalytic residue, while Thr26 and 
Gly27 provide attachment and support for the substrate. The tertiary structure of the protease 
assists the catalytic function. The flaps of the protease (residues 46 to 54 in C-SA PR) are 
conserved. Their function is to open and allow a substrate to enter the protease active site and 
close around the substrate to be cleaved. The motion of the flaps is guided by the hinge 
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regions (residues 35 to 42 and 57 to 61 in C-SA PR) (Wlodawer et al., 1989; Wlodawer and 
Vondrasek, 1998) (Figure 4 A).  
HIV proteases are vital in the proteolytic maturation of the virus. Without the protease, the 
polyprotein chains of the virus will not be cleaved into functional proteins and enzymes 
(Louis et al., 1994). The inhibition of the viral protease by protease inhibitors (PIs) prevents 
viral maturation (Figure 4 B). Thus far, protease inhibitors have proven to be useful in HIV 
treatment because they are prescribed, amongst other antiretroviral inhibitors, in highly active 
antiretroviral therapy (HAART) (Richman, 2001; De Clercq, 2006, 2009).  
HIV-1 retroviral proteases acquire mutations frequently due to the lack of proofreading ability of 
the viral reverse transcriptase. Beneficial variants are naturally selected for, as they confer drug 
resistance and improved viability of the virus. HIV-1 South African subtype C protease contains 
naturally occurring polymorphisms that make it different from other subtypes, such as the B 
subtype protease for which PIs were designed. The polymorphisms that make C-SA PR different 
from other subtypes also lower the susceptibility of the virus to PIs (Mosebi et al, 2008). Thus, 
antiretroviral protease inhibitors are comparatively less effective for patients harbouring C-SA PR 
and the corresponding virus subtype (Velázquez-Campoy et al, 2003; Mosebi et al, 2008). 
Additionally, subtype C proteases have been documented to be the most drug-resistant of the 
subtypes (Velázquez-Campoy et al., 2001). 
1.10 Double insertion mutant C-SA PR E35D↑G↑S 
The amino acid sequence for HIV-1 South African subtype C protease double insertion 
mutant E35D↑G↑S (henceforth known as E35D↑G↑S) was obtained from patient #2421 by 
Professor Lynn Morris (Head of the AIDS Unit at the National Institute for Communicable 
Diseases, South Africa). The patient received treatment with the nucleoside reverse 
transcriptase inhibitors (NRTIs), d4T (stavudine) and 3TC (lamivudine). The patient also 
received treatment with the non-nucleoside reverse transcriptase inhibitor (NNRTI), 
efavirenz. However, the patient was drug-naïve with respect to protease inhibitors. Keeping 
that in mind, it is important to investigate whether E35D↑G↑S has acquired mutations that 
weaken the interaction of the protease with protease inhibitors. Also, questions are raised 
concerning the effect of the insertions on the kinetic behaviour of the protease.    
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Figure 4: (A) HIV-1 South African subtype C protease and (B) Representation of an 
immature HIV-1 particle 
(A) C-SA PR in ribbon outlay (PDB ID 3U71). The two chains are yellow and magenta 
respectively. The hinge (cyan) and the flap (orange) regions are shown. The catalytic triad is 
Asp25 (red), Thr26 (blue) and Gly27 (green). Asp25 is the catalytic residue while Thr26 and 
Gly27 offer structural support to the substrate. The figure was generated with PyMOL v0.99 
(DeLano, 2002). (B) An immature HIV particle, consisting of unprocessed polyprotein chains 
due to the inhibition of the PRs by PIs. The figure was adapted from Richman, 2001. 
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The mutations in E35D↑G↑S occur in the hinge and flap regions of the protease. The 
background mutation M46L occurs in the flap while E35D, I36L and D60E occur in the 
hinge region (Figure 5 A and B). In addition, the two insertions occur in the hinge region of 
the protease. The hinge regions rotate the flaps, directing the opening and closing of the 
active site; therefore, governing the ease of access of substrates and inhibitors (Naicker et al., 
2014). Insertions in the hinge region, as well as, flap dynamics have been found to impact on 
the catalytic rate of proteases and their affinity for various substrates and inhibitors (Naicker 
et al., 2013; Naicker et al., 2014; Kozísek et al., 2008). In addition, mutations acquired in the 
recognition sequence of the viral polyprotein cleavage sites may provide better 
complementarity to the mutations in proteases. Overall, the acquisition of mutations can 
become beneficial to the virus (Doyon et al., 1996; Zhang et al., 1997; Mammano et al., 
1998; Kozísek et al., 2008).  
Three of the background mutations (I36L, M46L, and D60E) have been documented to make 
the binding of current protease inhibitors such as atazanavir (ATV) and ritonavir (RTV) 
inferior. Consequently, it is possible that E35D↑G↑S may exhibit reduced susceptibility to 
ATV and RTV. However, none of the mutations in E35D↑G↑S have been found to reduce 
susceptibility to darunavir (DRV) (Wensing et al., 2014; Standford University HIV Drug 
Resistance Database updated on the 9
th
 March 2015, accessed on 24
th
 August 2015 at: 
http://hivdb.stanford.edu/pages/download/resistanceMutations_handout.pdf).  
The homology structure prediction of E35D↑G↑S was generated using SWISS-MODEL 
(Figure 5 A) (Biasini et al., 2014; Arnold et al., 2006; Kiefer et al., 2009; Guex et al., 2009; 
Schwede et al., 2003). The amino acid sequence of the wild-type C-SA PR was aligned with 
that of E35D↑G↑S using ClustalW 2.1 (Larkin et al., 2007) (Figure 5 B). 
A Procheck (Laskowski et al., 1993, Laskowski et al., 2001) analysis of the E35D↑G↑S 
variant revealed that the percentage composition of beta sheets and alpha helices is 54% and 
6%, respectively, which is a slightly larger proportion when compared to C-SA PR (46%  
β-sheeted and 4% alpha helical). E35D↑G↑S has a molecular mass of 10880.9 Da (~11 kDa) 
and a pI = 9.32 (Gasteiger et al., 2005). 
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C-SA       PQITLWKRPLVSIKVGGQIKEALLDTGADDTVLEE—-INLPGKWKPKMIGGIGGFIKVRQ 58 
E35DGS     PQITLWKRPLVSIKVGGQIKEALLDTGADDTVLEDGSLNLPGKWKPKLIGGIGGFIKVRQ 60 
           **********************************:  :*********:************ 
 
C-SA       YDQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF 99 
E35DGS     YEQILIEICGKKAIGTVLVGPTPVNIIGRNMLTQLGCTLNF 101 
           *:*************************************** 
 
Figure 5: (A) SWISS-MODEL homology structure prediction of E35D↑G↑S alignment 
with C-SA PR and (B) ClustalW 2.1. sequence alignment of C-SA PR with E35D↑G↑S.  
C-SA PR (PDB ID 3U71 – yellow) is the wild type protease. The model prediction of the 
E35D↑G↑S variant was made using the PDB ID 3U71 structure as a template. The hinge 
regions of E35D↑G↑S are coloured in blue and the flaps are coloured in magenta. The 
insertions occur in the beginning of the hinge region between E35 and I36 (labelled blue 
spheres). The protein structure alignment (A) was produced using PyMOL v0.99 (DeLano, 
2002).   
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1.11 Active site of HIV-1 protease 
The active site of HIV-1 protease spans across eight subsites. In a directional order, the 
subsites are arranged as follows: S4, S3, S2, S1, S1', S2', S3' and S4' (prime notation 
denominates two chains). Namely: D29, G48, G27, and a H2O molecule co-ordinated by I50 
and I50', which positions the attached substrate in reach of the two catalytic residues, D25 
and D25'. The co-ordinated water molecule provides hydrogen-bond donors to make up both 
S1 and S1'. Thereafter, G27', G48' and D29' follow to constitute S2', S3' and S4' (Figure 6). 
The subsites make contacts with the following annotated positions of the peptide substrate: 
P4, P3, P2, P1, P1', P2' P3' and P4'. The cleavage of the substrate occurs at the catalytic site 
between P1 and P1' where D25 and D25' are found (Schechter and Berger, 1967; Wlodawer 
and Erickson, 1993; Wlodawer and Vondrasek, 1998). The number and strength of the 
hydrogen bonds made with the substrate may well determine the affinity of the enzyme for 
the substrate. Similarly, the affinity for PIs may also be affected. 
1.12 Catalytic mechanism of HIV-1 protease 
The active site of the protease contains Asp25 and Asp25', respectively, involved in the acid-
base hydrolysis of the substrate. Each of the residues belongs to one of the two chains, 
respectively. Only one of the two residues is protonated. This is a requirement for the binding 
of substrate. The protonation of a single residue is made possible by an increase in the pKa of 
the protonated aspartic acid residue from 3.1 to 5.2. Thus, the residue has a propensity to 
keep the bonded proton (Hyland et al., 1991). The protonated aspartic acid plays a role in 
hydrogen bonding of the substrate. The deprotonated aspartic acid residue deprotonates a 
water molecule which, in turn, nucleophilically attacks the carbonyl carbon of the scissile 
peptide bond recognised for hydrolysis. The reaction results in the formation of a tetrahedral 
transition-state intermediate (hydroxyethylamine isostere pivotal in drug design); whereby 
the carbonyl oxygen is now one electron deficient of the octet. The charged oxygen makes a 
double-bond with the carbonyl carbon thereby separating it from the amide end which was 
simultaneously protonated by the aspartic acid that has initially deprotonated the water 
molecule. In the end, the initially deprotonated aspartic acid which was subsequently 
protonated, is restored to the deprotonated state, ready to catalyse the hydrolysis of another 
scissile peptide bond (Figure 7) (Brik and Wong, 2003).  
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Figure 6: Schematic representation of the active site of HIV-1 protease 
The subsites on the enzyme are denoted by S4, S3, S2, S1, S1', S2', S3' and S4'. The 
corresponding positions taken by the peptide substrate are denoted: P4, P3, P2, P1, P1', P2' 
P3' and P4'. The amino acids forming subsites on each side of Asp25 and Asp25' help 
position the substrate while the catalytic aspartic acid residues cleave the scissile peptide 
bond between P1 and P1'. The prime annotation distinguishes two chains in the homodimeric 
protein. The figure was taken from Wlodawer and Erickson, 1993.  
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Figure 7: Catalytic mechanism of HIV-1 protease  
(A) Deprotonation of H2O by charged D', and nucleophilic attack on the carbon involved in 
the scissile peptide bond by the free hydroxyl group. Thus, the tetrahedral intermediate is 
formed. (B) Nucleophilic attack on carbonyl carbon by charged carbonyl oxygen, leaving the 
nitrogen atom charged, which in turn, nucleophilically attacks the hydrogen present on D' 
(from H2O). (C) The hydrolysed product is released by protonation of the leaving N-terminus 
of the cleaved scissile peptide bond (P1'). The protease resets and is ready to catalyse again. 
The figure was adapted from Brik and Wong, 2003. 
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1.13 Protease inhibitors to be tested 
Protease inhibitors were designed to mimic transition-state intermediates formed within a 
sequence recognised by HIV-1 proteases. However, they were designed so that the transition-
state intermediates could not be cleaved by HIV-1 proteases. Accordingly, a common feature 
of PIs is the presence of hydroxyethylamine isosteres. Hydroxyethylamine isosteres do not 
undergo peptide bond cleavage and are exclusively selected to mimic cleavage sites between 
Tyr-Pro and Phe-Pro, in order to achieve inhibitor specificity for HIV-1 protease (Wlodawer 
and Vondrasek, 1998).  
First generation PIs bind to proteases in an entropically driven manner (-TΔS < 0) and 
experience enthalpic resistance (ΔH > 0). Second generation PIs were designed to bind to 
HIV-1 proteases both enthalpically (ΔH < 0) and entropically favourable (Velázquez-
Campoy et al., 2001). Additionally, HIV-1 proteases are less effective at acquiring resistance 
to second generation PIs that bind to the backbone because mutations would not change the 
binding sites of the PIs with the protein backbone (Ghosh et al., 2007
1
; Ghosh et al., 2007
2
). 
However, the distance from PIs to the binding sites on the proteases may shift due to 
chemical properties brought upon by mutations. More likely than that, contact sites would 
shift due to insertion mutations. 
Due to the insertion mutations in E35D↑G↑S, second generation PIs are favoured for testing 
in this investigation. Darunavir binds to the backbone of HIV-1 proteases which makes it 
challenging for HIV-1 proteases to acquire drug resistance against darunavir (Ghosh et al., 
2007
1
; Ghosh et al., 2007
2
). Darunavir (Figure 8) was shown to bind to C-SA PR 
enthalpically favourable (ΔH = -79.91 kJ.mol-1) and entropically disfavoured  
(-TΔS = 8.93 kJ.mol-1) (Naicker et al., 2014). However, darunavir was shown to bind in an 
entropically favourable manner to HIV-1 proteases in multiple instances (Kožíšek et al., 
2014; Mittal et al., 2013). Nevertheless, it is intriguing to discover whether the insertion 
mutations of E35D↑G↑S would convey resistance to backbone-binding second generation 
PIs. Since the double insertion mutant protease, E35D↑G↑S, has no mutations that have been 
documented to provide resistance to darunavir (Wensing et al., 2014; Standford University 
HIV Drug Resistance Database updated on the 9
th
 March 2015, accessed on the 24
th
 August 
2015 at: http://hivdb.stanford.edu/pages/download/resistanceMutations_handout.pdf), the 
testing of darunavir may provide critical insight into drug resistance due to insertion 
mutations. 
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Figure 8: Darunavir complexed with HIV-1 protease (PDB ID 3OY4) 
Darunavir is hydrogen bonded to the backbone of the HIV-1 proteases subtype B variant. 
Moreover, the drug makes contacts with a coordinated water molecule at the conserved S1 
and S1' subsites (typical of PI binding). The oxygen atom in the hydroxyethylamine isostere 
is a hydrogen bond acceptor for the donor hydrogen on the protonated catalytic aspartic acid 
(D25 or D25' labelled in red). The hydrogen bond partners on darunavir are circled and 
annotated with the contacted residues. Darunavir makes 11 hydrogen bonds with the protease 
subsites in this instance. The chemical structure of darunavir was produced using PubChem 
Sketcher V2.4 (accessed at http://pubchem.ncbi.nlm.nih.gov/edit2/index.html, on 18
th
 August 
2015) with SMILES notation obtained from Drugbank ID DB01264. The crystal structure of 
complexed darunavir was analysed and displayed using PyMOL V0.99. Labels are colour-
coded with the chain of the homodimeric enzyme. 
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Atazanavir (Figure 9 A) and ritonavir (Figure 9 B) bind exothermically to C-SA PR, as it is 
expected of second generation backbone binding PIs (Velázquez-Campoy et al., 2001; 
Velázquez-Campoy et al., 2003). However, ritonavir was also shown to bind endothermically 
(Naicker et al., 2014). This could be because the experimentally determined binding enthalpy 
is close to zero. Thus, data fitting errors could indicate favourable or unfavourable enthalpy. 
Nevertheless, there is reasonable certainty that atazanavir and ritonavir bind in an 
entropically driven manner.  
The size of the inhibitors may affect binding energetics to proteases. Darunavir being a 
smaller molecule (MW = ~547 g/mol) binds enthalpically driven because it makes more 
contacts than it disrupts water molecules bonded to the protein (Kožíšek et al., 2014; Mittal et 
al., 2013). Atazanavir (MW = ~704 g/mol) and ritonavir (MW = ~720 g/mol) are relatively 
large inhibitors. Indeed the large size of the inhibitors contributes to the positive entropy 
generated upon binding, due to the displacement of ordered water molecules. At the same 
time though, the displacement of too many ordered water molecules around the protease 
active site may be enthalpically disfavoured. That is because disruption of hydrogen bonds 
requires energy. This can justify why the two drugs may bind endothermically.  
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Figure 9: Binding of atazanavir (A) and ritonavir (B) to HIV-1 protease 
Atazanavir (Drugbank ID DB01072; PDB ID 3EKY) and ritonavir (Drugbank ID DB00503; 
PDB ID 1HXW) bind the backbone of HIV-1 protease subtype B. The drugs are larger in 
comparison to darunavir. Therefore, the drugs may displace more water molecules bonded to 
the protein, requiring energy, making the binding less favourable enthalpically than 
darunavir. Atazanavir makes 12 hydrogen bonds with the subsites while ritonavir makes 10. 
The hydrogen bonding partners of the two inhibitors are circled and annotated with the 
bonded residues. The water molecule providing the S1 and S1' subsites, is labelled in 
magenta. The labels are colour-coded with the chains and catalytic residues.  
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2 Aim and Objectives 
2.1 Aim 
The aim of the proposed experimental research was to determine the effect of the mutations 
observed in E35D↑G↑S in comparison to the wild type C-SA PR with regards to structure, 
kinetic activity and drug resistance. This would shed light on the effect of hinge insertions on 
the drug binding mechanism of HIV-1 protease subtype C as well as HIV-1 proteases in 
general.  
2.2 Objectives 
 Solubilisation of lyophilised E35D↑G↑S 
 Secondary structure characterisation using far-UV circular dichroism 
 Tertiary structure characterisation using intrinsic fluorescence spectroscopy 
 Kinetic characterisation (specific activity; KM; kcat; kcat / KM) monitoring cleavage of 
substrate over time 
 IC50 and Ki determination monitoring cleavage of substrate over time  
 Binding thermodynamic characterisation using isothermal titration calorimetry 
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3 Methods and Materials 
3.1 Materials 
The protease inhibitors used in this research, namely, atazanavir, ritonavir and darunavir were 
obtained from the NIH AIDS Reagent Programme. The aspartic protease inhibitor, acetyl 
pepstatin, was obtained from MINTEK, South Africa. The fluorogenic substrate used (Abz-
Arg-Val-Nle-Phe(NO2)-Glu-Ala-Nle-NH2) was obtained from Synpeptide
®
, China. 
Ampicillin, chloramphenicol and PMSF were obtained from Sigma-Aldrich
®
, South Africa. 
3.2 Solubilisation of chemically synthesised, lyophilised E35D↑G↑S and 
degradation studies 
A lyophilised sample of chemically synthesised E35D↑G↑S was kindly provided by 
Professor Fernando Albericio (University of Barcelona, Spain). The lyophilised sample did 
not dissolve in deionised water or activity buffer (10 mM sodium acetate buffer, pH 5.00, 
containing 0.02% sodium azide). It was assumed that the chemically synthesised protein was 
misfolded. Subsequently, the protein was unfolded in 10 mM Tris buffer, pH 8.00, containing 
0.02% sodium azide, 2 mM dithiothreitol (DTT) as a reducing agent and 6 M guanidinium 
chloride or 8 M urea as a denaturant. Refolding was achieved via overnight dialysis. 
However, the amount of enzyme present was barely detectable on SDS-PAGE (described in 
section 3.2) following overnight dialysis.  Moreover, degradation was visible suggesting 
autocatalytic activity.  
Degradation studies were set up to determine the shortest dialysis period required for the 
E35D↑G↑S protease to refold and become active, in order to limit the time permitting 
autocatalysis. Degradation studies involved the variation of the period allowed for dialysis-
assisted refolding. The protease was unfolded in 10 mM Tris-HCl buffer, pH 8.00, containing 
2 mM DTT and 8 M urea. The unfolded protease was dialysed against 10 mM sodium acetate 
buffer, pH 5.00, containing 0.02% sodium azide.  Dialysed protease samples were taken at 0, 
0.25, 0.5, 0.75, 1, 2, 3, 4, 5, 6, 7 and 24 hours and immediately placed in reducing sample 
buffer for SDS-PAGE (described in section 3.2). Densitometry analyses of the 
electrophoresed gels were performed using GelAnalyzer.  The dialysis time was reduced to  
1 hour and 15 minutes. It was then necessary to determine the percentage of protein that 
remained active after 1 h and 15 minutes of dialysis. Thus, the enzyme was titrated with 
acetyl pepstatin using active site titration calorimetry (described in section 3.12.1). 
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3.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is a common analytical technique described by Laemmli (Laemmli, 1970).  
SDS-PAGE separates proteins by size since the sodium-dodecyl sulfate imparts proportional 
weight and negative charge to proteins based on the size of each protein species. Proteins are 
thus pulled to the anode when electric current is applied. It has been documented in a 
modified SDS-PAGE protocol, published by Schägger, 2006, that tricine makes a better 
trailing ion than glycine as it achieves better separation of proteins in the lower molecular 
weight range (smaller than 20 kDa) (Schägger, 2006; Haider et al., 2011). The monomeric 
molecular weight of the HIV-1 proteases used in this study is approximately  
11 kDa (Gasteiger et al., 2005). Therefore, tricine SDS-PAGE was used to assess the 
presence and to a lesser extent, the purity of proteins according to Schägger (Schägger, 
2006). Gels (10% and 16%), sample buffer (12% SDS, 6% β-mercaptoethanol, 30% glycerol, 
0.05% Coomassie blue G-250, 150 mM Tris-HCl pH 7.00), fixing and staining solution 
(0.025% Coomassie G-250, 50% methanol and 10% acetic acid) and de-stain solution (10% 
acetic acid) were prepared. The cathode buffer contained 100 mM Tris, 100 mM Tricine and 
0.1% SDS. The anode buffer contained 100 mM Tris-HCl pH 8.9. A 10% polyacrylamide gel 
was initially used to electrophorese the lyophilised E35D↑G↑S sample before and after 
overnight dialysis-assisted refolding. Thereafter, 16% polyacrylamide gels were used for 
further studies. The Page Ruler Prestained Protein Ladder (Thermoscientific®) was used as the 
molecular weight maker. 
3.4 Escherichia coli BL21(DE3)pLysS cells and pET-11b vector encoding  
C-SA PR variants 
Escherichia coli BL21(DE3)pLysS is a protein expression cell line particularly useful when 
expressing cytotoxic proteins. That is because the T7 lysozyme, encoded by the pLysS 
lysogen, interferes with the elongation function of the T7 RNA polymerase encoded by the 
DE3 lysogen. Thus, basal expression of (cytotoxic) proteins is minimised (Moffatt & Studier, 
1987; Stano & Patel, 2004; Studier & Moffatt, 1986). The pLysS lysogen also contains a 
selectable marker that confers resistance to chloramphenicol. Chloramphenicol (35 μg/ μl) 
was used in all experimental cultures inoculated with E. coli BL21(DE3)pLysS.  
The pET-11b vector (Novagen
®
) is used for the expression of recombinant proteins. The 
pET-11b expression vector confers resistance to ampicillin. Therefore, all the broth and agar 
plates that were used for inoculating or plating BL21(DE3)pLysS transformed with the  
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pET-11b vector were supplemented with 100 μg/ μl ampicillin. The vector also houses a T7 
promoter upstream from the recombinant gene inserted into the multiple cloning site. Protein 
overexpression in BL21(DE3)pLysS transformed with pET-11b occurs by inducing 
overexpression of the T7 RNA polymerase (harboured in the DE3 lysogen) with  
isopropyl β-D-1-thiogalactopyranoside (IPTG).  
The C-SA PR construct, incorporating the Q7K autocatalysis-resistant mutation (Mildner et 
al., 1994) was produced in pET-11b plasmid in our laboratory via site-directed mutagenesis 
by Mosebi (Mosebi et al., 2008). However, the Q7K mutation does not completely prevent 
autocatalysis. The Q7K mutation has been kept in both HIV-1 protease variants used in this 
study. Prior to the protease sequence, there is a 12 amino acid long gag-pol recognition 
sequence that starts with a methionine residue (start codon) since the protease lacks a start 
codon. As such, the protease autoprocesses out of the gag-pol recognition sequence after 
folding and dimerisation.  
The lyophilised sample of E35D↑G↑S was insufficient; therefore, a gene construct was 
synthesised in order to continue with the proposed aims and objectives. The E35D↑G↑S 
variant gene sequence was designed using the C-SA PR gene sequence as a template so that 
codon differences between the two variant protease gene constructs were minimised (shown 
is supplementary material S1). The pET-11b vector encoding E35D↑G↑S was synthesised by 
GenScript (Piscataway, USA). Site-directed mutagenesis was not a suitable technique for the 
production of the E35D↑G↑S variant due to numerous mutations and insertions in the variant 
which would be time consuming and costly.  
A D25A active site mutation of C-SA PR and E35D↑G↑S were generated through site-
directed mutagenesis. The active site mutants were generated as a result of the unsuccessful 
expression of the E35D↑G↑S variant. The D25A mutation inactivates the aspartic HIV-1 
protease (Koh et al., 2011). As such, the active site mutant was expected to express better 
because the autocatalytic function of the protease is muted. 
3.5 Primer design and site-directed mutagenesis used to create the D25A active 
site mutant 
Site-directed mutagenesis is a technique involving the use of polymerase chain reaction 
(PCR). However, the primers used contain a mismatched base where a single mutation will 
be introduced in the amplified product by the polymerase. Site-directed mutagenesis was 
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performed using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent 
Technologies) according to the manufacturer’s instructions. The initial denaturation step was 
carried out at 95 °C for 2 minutes. Thereafter, 18 cycles of denaturation (95 °C for 20 s), 
annealing (60 °C for 10 s) and elongation (68 °C for 3.5 minutes) were performed. A final 
elongation step was carried out a t 68 °C for 5 minutes.  
The forward and reverse primers used to introduce the D25A mutation were designed 
manually. The primers were designed separately for C-SA PR and E35D↑G↑S based on the 
sequence identified by Inqaba Biotec
TM
 (Pretoria, South Africa) for each variant. The two 
sets of primers were aligned with ClustalX 2.0 (Larkin, 2007) in order to verify if it was 
necessary to obtain two different sets of primers or if one set would be suitable for both 
variants. It was deduced that one set of primers would suit both variants since they were 
identical. In the forward primer, the adenine nucleotide was changed to a cytosine nucleotide. 
In the reverse primer, the thymine nucleotide was changed to a guanine nucleotide underlined 
in the sequence.  The changed nucleotides allow for the aspartic acid residue at position 25 to 
be mutated to an alanine residue. The changed nucleotides are underlined in the sequences of 
the primers. The forward (5' CAAAGAAGCTCTGCTGGCCACTGGCGCTGACGAC 3') 
and reverse (5' GTCGTCAGCGCCAGTGGCCAGCAGAGCTTCTTTG 3') primers were 
checked with OligoCalc for high melting temperature (Tm). The Tm was found to be 80 ˚C 
(> 78 °C, as recommended by the manufacturer of the kit). Primers were synthesised by 
Inqaba Biotec
TM
 (Pretoria, South Africa). 
3.6 Transformation of Escherichia coli BL21(DE3)pLysS with pET-11b encoding 
protease variants 
Transformation was done using the heat-shock method. Eighty microlitres of chemically 
competent BL21(DE3)pLysS cells (provided in the laboratory) were thawed on ice. Upon 
complete thawing, 2 μl of 189 ng/ µl DNA (5 μl of 1 ng/ µl DNA in the case of site-directed 
mutagenesis product) was added to the cells and mixed gently by tapping. The cells were then 
incubated on ice for 30 minutes. Thereafter, the cells were heat-shocked at 42 ˚C for 45 
seconds followed by immediate incubation on ice for 2 minutes. Four hundred microlitres of 
SOC media (pre-warmed at 37 ˚C) was then added. SOC media contains 2% (w/ v) tryptone, 
0.5% (w/ v) yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 20 
mM glucose. SOC media improves transformation efficacy (Hanahan, 1983). After the 
addition of SOC media, the cells were incubated at 37 ˚C with shaking at 230 rpm for 1 hour. 
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One hundred microlitres of the culture were plated on LB plates (1.5 % agar) supplemented 
with the appropriate antibiotics. The remaining volume of culture was pelleted for 2 minutes 
at 10 000 x g using a Spectrafuge 24D microcentrifuge (Labnet International Inc.). Two 
hundred microlitres of the supernatant were discarded and 100 μl of the re-suspended cells 
were plated. Single colonies were selected and inoculated overnight in LB-Lennox media 
which contains 1% (w/ v) tryptone, 0.5% (w/ v) yeast extract and 0.5% (w/ v) NaCl (Lennox, 
1955). Glycerol stocks were made by an equal-volume dilution of the overnight culture with 
a sterile 80% glycerol solution. Glycerol stocks were stored at -80 ˚C. The plasmid was 
extracted from an overnight culture with the GeneJET Plasmid Miniprep Kit 
(Thermoscientific
®
) and sent for sequencing. All cells stocks used have been verified and 
confirmed to be transformed with the pET-11b plasmid containing the correct DNA 
sequence. All sequencing was done by Inqaba Biotec
TM
 (Pretoria, South Africa). DNA 
sequences were translated using ExPASy – Translate (Gasteiger et al., 2003). Sequence 
analysis was performed using ClustalX 2.0 (Larkin, 2007). There were no amino acid 
mismatches between the expected sequence and the sequence contained within the cell 
stocks. 
3.7 Expression trials of E35D↑G↑S and E35D↑G↑S D25A  
Expression trials were performed in order to identify the appropriate conditions for 
expression of E35D↑G↑S. Briefly, 1.5 ml of bacterial cultures grown in LB-Lennox  were 
pelleted using a Spectrafuge 24D microcentrifuge (Labnet International Inc.) at  
10, 000 x g for 2 minutes. The cells were re-suspended in 175 µl of 10 mM Tris-HCl buffer, 
pH 8.00, containing 2 mM EDTA and 1 mM PMSF. Thereafter, the samples were frozen at  
-20 ˚C. The cells were thawed at room temperature to aid cell lysis. The thawed cells were 
incubated for ten minutes at room temperature with 1 µg/ ml DNAse and 10 mM MgCl2. The 
cells were further lysed by sonication using a XL-2000 series sonicator manufactured by 
Misonix Ultrasonic Liquid Processors. The cells were sonicated once for ten seconds at  
12 Watts. The lysed cells were centrifuged for 10 minutes at 12, 000 x g using a Spectrafuge 
24D microcentrifuge (Labnet International Inc.). The supernatant was mixed with an equal 
volume of reducing SDS-PAGE sample buffer and electrophoresed as per the protocol 
described by Schägger (Schägger, 2006). The pellet was re-suspended in 165 µl of Tris-HCl 
buffer, pH 8.00, containing 2 mM EDTA and 1 mM PMSF, thereafter, mixed with an equal 
volume of reducing sample buffer. Ten microlitres of the expression trials samples containing 
reducing sample buffer were electrophoresed using 16% polyacrylamide gels.  
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In the expression trials of E35D↑G↑S, the effect of temperature (20 and 37 ˚C), IPTG 
concentration (0, 0.3, 0.6 and 1.0 mM) and induction periods (4 hours, 6 hours and, 
overnight) were tested in E. coli BL21(DE3)pLysS grown in LB-Lennox. Since 
overexpression was unsuccessful, a E35D↑G↑S D25A active site mutant was created. The 
inactive protein was subjected to expression trials using E. coli BL21(DE3)pLysS and E. coli 
Rosetta 2
®
 cells. The Rosetta 2
® 
cell line contains seven rare codons. In light of that, the 
Rosetta 2
®
 cell line was tested to verify whether codon incompatibility prevents the 
expression of the E35D↑G↑S protease. The Rosetta 2® cell line was tested in LB-Lennox and 
LB-Miller media. LB-Miller media contains 1% (w/ v) tryptone, 0.5% (w/ v) yeast extract 
and 1% (w/ v) NaCl. The E. coli Rosetta 2
® 
cell line was a kind gift from Dr. Sylvia Fanucchi 
(University of the Witwatersrand, South Africa).   
3.8 Overexpression of C-SA PR 
Glycerol stocks were inoculated and grown in LB-Lennox media overnight. Fresh media was 
inoculated with 1% (v/ v) of the overnight culture. At OD600 nm = 0.6, overexpression was 
induced with 1 mM IPTG for 4 hours at 37 °C. Cells were pelleted at 4 ˚C via centrifugation 
at 5, 000 x g with Sorval Lynx 4000 Centrifuge (Thermoscientific
®
). The cells were re-
suspended in 1% (v/ v) of the culture volume, in 10 mM Tris-HCl buffer, pH 8.00, containing 
2 mM EDTA and 1 mM PMSF. The cells were frozen at -20 ˚C. The frozen cells were 
thawed at room temperature to assist with cell lysis. The cells were further lysed by 
sonication at 12 Watts using a XL-2000 series sonicator manufactured by Misonix Ultrasonic 
Liquid Processors. Ten sonication cycles were performed. The cycles were 1 minute long 
alternating with 1 minute rest periods. Prior to sonication, the samples were pre-chilled on ice 
for 30 minutes and kept on ice throughout the sonication procedure. 
3.9 Pre-modified purification of C-SA PR 
After lysing the cells containing C-SA PR, the insoluble fraction was pelleted for 30 minutes 
at 24, 000 x g at 4 °C using a Sorval Lynx 4000 Centrifuge (Thermoscientific
®
). The pellet, 
which contained C-SA PR inclusion bodies, was re-suspended (twice) in 10 mM Tris-HCl 
buffer, pH 8.00, containing 2 mM EDTA and 1 mM PMSF with added 1% (v/ v) Triton-X 
100. The solution was then centrifuged for 30 minutes at 24, 000 x g at 4 °C. This process 
removes the remaining lipid bilayer and any other weakly soluble contaminants with 
hydrophobic properties. The supernatant was discarded. The pellet was then re-suspended in 
40 ml of 10 mM Tris-HCl buffer, pH 8.00, containing 8 M urea and 2 mM DTT for complete 
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denaturation of the inclusion bodies containing C-SA PR. The denatured inclusion bodies 
were refolded via dialysis in 10 mM formic acid with 10% glycerol and 0.02% sodium azide. 
The refolded protease was then activated by dialysis into activity buffer (10 mM sodium 
acetate buffer, pH 5.00, containing 0.02% sodium azide). A major part of contaminant 
precipitated when dialysing in activity buffer. The precipitant was removed by centrifugation 
for 30 minutes at 24, 000 x g at 4 °C. The active protease was purified using a 5 ml  
CM-sepharose column (GE Healthcare) with the use of an AKTA Prime Plus
®
 
chromatographic system manufactured by GE Healthcare. The eluted protease was 
concentrated using a 50 ml amicon
®
 8050 pressure cell. A 3, 000 Da cut-off regenerated 
cellulose membrane (Millipore) was used for concentrating the protein sample. The protein 
was concentrated at a pressure of 300 kPa using nitrogen gas, with constant stirring at  
200 rpm.  
3.10 Modified purification of C-SA PR 
Steps were followed as per the pre-modified purification of C-SA PR. However, the activity 
buffer used for dialysis was modified by adding 2 mM DTT and 2 mM NaCl. The added 
components presumably disrupt non-specific protein-protein interactions. In all other aspects, 
the protocol remained unchanged when compared to the pre-modified purification protocol 
(described in section 3.8).  
In the course of optimising the purification of C-SA PR and decreasing autocatalytic cleavage 
various approaches were taken. The rate of re-folding was increased using 1% SDS as a 
denaturant of inclusion bodies (in the presence of 2 mM DTT) (Schlager et al., 2012). The 
denatured protein sample was refolded in dialysis buffer (10 mM formic acid with 10% 
glycerol and 0.02% sodium azide). The rapid refolding procedure produced soluble protease. 
However, increased amounts of contaminating proteins were salting in as well. In addition, 
various pHs were used in activation buffers (10 mM Tris-HCl, pH 7.00, pH 7.5 and pH 8.00 
containing 0.02% sodium azide) in order to reduce autocatalytic activity of the protease. 
Varying pHs changes the protonation state of the catalytic aspartic acid, taking advantage of 
the catalytic mechanism of HIV-1 protease (Hyland et al., 1991). However, these conditions 
did not prove to be effective because the protease produced SDS-PAGE profiles typical of 
autocatalysis (data not shown). 
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3.11 Protein concentration determination 
The concentration of protease was determined spectrophotometrically. The absorbance of 
protein samples was taken at 280 nm using a Jasco V-630 Spectrophotometer. The 
concentration was calculated using the Beer-Lambert law (equation 1).  
A = εcl                      (equation 1) 
Where A is the absorbance, ε is the molar extinction coefficient, c is the molar concentration 
and l is the path length (1 centimetre). 
The theoretical extinction coefficient of the dimeric C-SA PR (25, 230 M
-1
.cm
-1
) was 
determined using ProtParam (Gasteiger et al., 2005). The absorbance at 280 nm of the 
dialysate was subtracted as a blank reading. In addition, light scattering due to aggregates was 
corrected for by subtracting the absorbance reading at 340 nm. The concentration of protein 
was determined for every experiment.  
3.12 Size-exclusion ultra-fast liquid chromatography (UFLC) 
The purity of C-SA PR was analysed using size-exclusion ultra-fast liquid chromatography 
using the ultra-fast liquid chromatograph manufactured by SHIMADZU
®
. The samples were 
chromatographed using a TSKGEL SUPER SW2000 (Sigma-Aldrich
®
). The column has a 
separation range from 5 kDa to 150 kDa. The column combines the properties of reverse-
phase and normal phase resins. That is, the resin is silica-based with hydrophilic components. 
The hydrophilic phase prevents the formation of hydrophobic interactions between proteins 
and the silica gel, allowing proteins to migrate with the mobile phase. 
Samples were chromatographed in 10 mM sodium acetate buffer, pH 5.00, containing 0.02% 
sodium azide and either 150 mM or 300 mM NaCl. The concentration of protein used was 20 
µM (matching the concentration used for active site titration experiments). The samples were 
eluted at a flow rate of 0.2 ml/ min. The molecular weight standard used was MWGF70 
(Sigma-Aldrich
®
) containing aprotinin (6.5 kDa), cytochrome c (12.4 kDa), carbonic 
anhydrase (29 kDa) and bovine serum albumin (66 kDa).  
3.13 Isothermal titration calorimetry 
Isothermal titration calorimetry is a highly sensitive calorimetric technique used for 
determining binding energetics of interacting macromolecules. The micro-calorimeter detects 
enthalpic changes (ΔH) during titrations. Changes in enthalpy due to chemical interactions in 
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the sample cell trigger the power feedback system to compensate for emerging heat changes. 
It is in this manner that the reference cell and sample cell are kept at isothermic conditions. 
The system comprising of the two cells is isolated by an adiabatic jacket (Holdgate & Ward, 
2005; Núñez et al., 2012) (Figure 10). A titration entails a series of injections into the sample 
cell. The reference cell contains the solvent alone which is usually deionised water. That is, if 
the buffer system does not have a very large osmolarity or ionic strength (Duff et al., 2011). 
In which case, the buffer should be loaded into the reference cell instead of solvent alone. 
The injection volumes are user-defined. The purity of the reactants must be of highest 
attainable quality. The concentrations of the reactants must be prepared and known with the 
highest possible accuracy. The data-points that are obtained are equivalent to the heat 
compensated by the instrument into the adiabatic system so that the temperature of the system 
is kept constant. The concentration of titrand is best measured spectrophotometrically using a 
sample extracted from the sample cell after loading it, in order to account for dilution by 
residual dialysis buffer used to wash the sample cell. 
The injected solution (titrant) is usually a ligand and it is at a higher concentration than the 
reacting counterpart in the sample cell (titrand) which is usually a protein or enzyme. This is 
because the protein or enzyme must be saturated with ligand several injections prior to the 
end of the titration experiment. That is, in order to accurately determine the reaction 
equilibrium constant (Ka) and the heats of dilution of the ligand into buffer.  
The heats of dilution of titrants are often measured in blank titrations of ligand into buffer. 
However, the heats of each injection are due to several factors: binding, ligand dilution and, 
macromolecule dilution and mixing of components due to stirring (Holdgate & Ward, 2005). 
It is for this reason that heats of dilution are more accurate at the end of the experimental 
titration as opposed to the blank titration. 
Optimally, a thermogram is sigmoidal in shape. For that, experimental design must be 
planned to render a Wiseman C-value (C = Ka x [titrand] x N) between 1 and 1000 for the 
data set to fit a sigmoidal equation (Wiseman et al., 1989; Turnbull et al., 2003) where Ka is 
the binding constant at equilibrium and N is the binding stoichiometry. However, a C-value 
between 10 and 500 is optimal. For strong binders (Ka ≥ 10
8 
M
-1
), the C-value is commonly 
between 100 and 500. This implies that the titrant concentration may not be much higher or 
lower than the concentration of titrand (Freyer and Lewis, 2008). Moreover, the 
concentration of protein for ITC experiments is set to be 10 to 50 times larger than the  
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Figure 10: Schematic representation of a typical micro-calorimeter 
The reference and sample cells are insulated by the adiabatic jacket. Changes in enthalpy 
(ΔH) trigger thermal compensation of power feedback to the sample cell. The two cells are 
brought back to an isothermal state in this manner. The syringe injects titrant into the sample 
cell containing the titrand. Heat is generated by binding, titrant dilution, titrand dilution and, 
mixing of titrant with titrand. Figure adapted from Núñez et al., 2012. 
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dissociation constant of the ligand. Similarly, the concentration of ligand is set to be 10 to 
times larger than the concentration of protein. However, the concentration of ligand may 
often be set to be over 100 times larger than the concentration of protein for weak binders  
(Ka ≤ 10
4 
M
-1
) (Freyer and Lewis, 2008). 
The pre- and post-transition regions of a titration curve directly determine the change in 
enthalpy (ΔH) of the reaction/ binding-event monitored. Knowing the molar enthalpy, the 
concentration of complexed molecules is determined. In light of that, by knowing the 
concentration of un-complexed molecules, the equilibrium constant (Ka) can be established 
(Figure 11) (Núñez et al., 2012). The Ka is established from the average of the Ka values at 
each point on the transition region of the titration curve. It is for this reason that the transition 
region, ideally, should be well-populated by data points. Ultimately, the change in entropy 
(ΔS) and change in Gibbs free-energy (ΔG) can be determined using equation 2 (Freyer and 
Lewis, 2008). 
ΔG = ΔH – TΔS = - RTlnKa                (equation 2) 
Where ΔG is the Gibbs free-energy of the reaction, ΔH is the enthalpy of the reaction, T is the 
absolute temperature (K) of the reaction, ΔS is the entropy of the reaction, R is the gas 
constant (8.314 J mol
-1
 K
-1
) and Ka is the equilibrium constant of the reaction. The inverse of 
Ka is Kd which is the dissociation constant of the enzyme-inhibitor complex. 
The inflection point of the titration curve directly indicates the point in the titration where the 
concentration of ligand is equal to that of the macromolecule. With the aid of this, the binding 
stoichiometry (N) and percentage of active sites are directly established in active site titration 
experiments (Figure 11) (Freyer and Lewis, 2008, Núñez et al., 2012; Holdgate & Ward, 
2005). 
3.13.1 Active site titration calorimetry 
In order to account for autocatalysis of the protease and misfolded specimens, active-site 
titration experiments were performed. The data was used to determine the concentration of 
active protein for subsequent analytical experiments. Active site titration experiments are 
performed with ligand-protein systems that have well-established binding energetics 
parameters. The binding energetics parameters confirm whether the titration experiment was 
performed appropriately; thus, indicating whether the determined binding stoichiometry (N)  
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Figure 11: Parameters determined directly using isothermal titration calorimetry 
The pre- and post-transition regions of the titration curve are used in determining the molar 
enthalpy (ΔH) of the reaction monitored. The molar enthalpy is used to determine the amount 
of protein-ligand complex formed at each injection. Thus, the transition region is used to 
determine the equilibrium constant (Ka) of the binding event. The inflection point of the 
sigmoidal curve occurs when the concentration of ligand is equal to that of the 
macromolecule. The inflection point is used to determine the stoichiometry (N) and 
percentage of active sites. Figure adapted from Núñez et al., 2012. 
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was accurate. More than that, the binding energetic parameters obtained in these typical 
titrations are used as fixed parameters when fitting displacement titration data sets. 
Acetyl-pepstatin is a well-documented HIV-1 protease inhibitor (Seelmeier et al., 1988). 
Acetyl-pepstatin (8 mM) stocks were made by dissolving in 9 mM NaOH. The active-site 
titration experiment was conducted as follows: PR (20 µM) was titrated with 35 injections of 
7 µl acetyl-pepstatin (200 µM). The dialysis buffer contained 10 mM sodium acetate, pH 
5.00, containing 0.02% sodium azide. The DTT was dialysed out particularly for ITC because 
the oxidisation of DTT introduces noise into the baseline of ITC data. The reference cell 
contained deionised water. All solutions were degassed. The volume of the syringe used in all 
ITC experiments was 250 µl. All titrations were performed using a standard volume Nano 
ITC (TA Instruments). Data were fitted with NanoAnalyze (TA Instruments) using the 
independent model, also known as the single-site model or one-to-one model, as the fitting 
model.  
3.13.2 Displacement titration calorimetry (DTC) 
Protease inhibitors bind with high affinity to HIV-1 proteases, having dissociation constants  
(1/ Ka = Kd) in the nanomolar and picomolar range. As such, the determination of energetic 
parameters of inhibitors, especially Ka, is impaired in terms of accuracy when directly titrated 
because the protein saturates with proportionally very low amounts of inhibitor. Thus, the 
transition regions of the titration curves obtained are underpopulated by data points. In order 
to resolve this problem, it is necessary to titrate PIs into titrands composed of PR complexed 
with a weaker inhibitor like acetyl-pepstatin. The high affinity protease inhibitors displace 
acetyl-pepstatin. These experiments are known as displacement titration experiments 
(Velazquez-Campoy & Freire, 2006)  
Stocks of atazanavir, ritonavir and darunavir had a 10 mM concentration dissolved in 100% 
DMSO. Atazanavir, ritonavir and darunavir were titrated against C-SA PR complexed with 
acetyl-pepstatin in displacement titration calorimetry experiments. The protease was initially 
incubated with 400 µM acetyl-pepstatin in a 10 mM sodium acetate buffer, pH 5.00, 
containing 0.02% sodium azide and 2% dimethyl sulfoxide (DMSO). The DMSO was used to 
solubilise the hydrophobic inhibitors. Buffers were matched for all reactants. The 
concentration of protease and inhibitor used was altered for individual experiments in order 
to obtain well-defined, data-populated regions of titration curves. In general, the stronger the 
34 
 
affinity of a ligand for a macromolecule, the lower the concentration and/ or injection volume 
of ligand was set to be. This prevents premature saturation of the protease. 
The injection volumes and concentrations of ligand and protein for each experiment were as 
follows: seven microlitre injections of 200 µM atazanavir were titrated into 18 µM C-SA PR. 
Six microliter injections of 110 µM ritonavir were titrated into 18 µM C-SA PR. Five 
microlitre injections of 110 µM darunavir were titrated into 15 µM C-SA PR. The number of 
injections was maximised for a 250 µl syringe. Data were fitted with NanoAnalyze (TA 
Instruments) using the competitive replacement fitting model. 
3.14 Homology modelling and secondary structure prediction 
Homology modelling is a technique used to generate 3D structures from primary-structure of 
proteins using experimentally determined structures as templates. The generated structures 
compensate for the absence of experimentally determined structures (Biasini et al., 2014).  
The 3D structure of E35D↑G↑S was generated using SWISS-MODEL and the amino acid 
sequence of E35D↑G↑S. The model was generated using C-SA PR (PDB 3U71) as a template 
based on the highest sequence identity (96%). The Global Model Quality Estimation (ranging 
from 0 to 1) was 0.98, indicating a fairly reliable prediction of the structure based on the 
template used (Biasini et al., 2014; Arnold et al., 2006; Kiefer et al., 2009; Guex et al., 2009; 
Schwede et al., 2003).  The structure was used to depict the location of the insertions in 
Figure 5 A. 
The secondary structure prediction of the E35D↑G↑S model was made using PROCHECK 
(Laskowski et al., 1993, Laskowski et al., 2001). The predicted secondary structure content 
was used in the introduction section to elaborate the predicted aspects of E35D↑G↑S as well 
as to compare with the secondary structure of C-SA PR, thus, allowing expectations of 
circular dichroism experiments.  
3.15 Secondary structure characterisation using far-UV circular dichroism  
Circular dichroism (CD) spectroscopy is used to quantify the absorbance of left and right 
circularly polarised light. The differential absorbance of left and right circularly polarised 
light is known as ellipticity. Chiral molecules, such as those forming peptide bonds, absorb 
differentially polarised light in the far-UV region (240 - 180 nm). This is characteristic of 
how amino acids fold to form particular secondary structure elements (Woody, 1995; Kelly & 
Price, 2000). Typical ellipticity profiles have been documented. Anti-parallel β-sheets 
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produce a peak at 190 nm and a trough at ~216 nm. Alpha helices produce a relatively higher 
peak at ~190 nm, a trough at 222 nm and a trough at ~209 nm. Random coils produce a 
trough at ~195 nm (Greenfield, 1996, 2006; Kelly & Price, 2000). 
In the event that a protein consists mostly of beta sheets and random coils, it is likely that 
destructive interference would occur in the region between 190 - 195 nm. HIV-1 protease is 
such a protein (Figure 12). Therefore, the ellipticity profile of the proteases being studied 
should characteristically trough at ~216 nm. It is also expected that the ellipticity profile of 
E35D↑G↑S would reveal more random coil content than C-SA PR. This expectation is based 
on a homology model (Figure 5 A) built with SWISS-MODEL (Biasini et al., 2014; Arnold 
et al., 2006; Kiefer et al., 2009; Guex et al., 2009; Schwede et al., 2003) which depicts the 
insertions as a random coil extension of the flap region of the protease.  
The far-UV CD spectrum of C-SA PR was obtained using a Jasco J-1500 CD 
Spectrophotometer. The experimental parameters included a 0.5 nm band width and a data 
pitch of 0.2 nm. The path length of the cuvette was 0.2 mm. The ellipticity spectrum was 
taken from 180 to 250 nm (average of five accumulations). The mean residue ellipticity  
(MRE, deg.cm
2
.dmol
-1
) was calculated using equation 3. 
MRE =  
        
   
                             (equation 3) 
Where θ is the ellipticity in millidegrees (mdeg), C is the mM concentration of protein (0.015 
mM for C-SA PR), n is the number of amino acids in the protein (198 per dimeric C-SA PR) 
and l is the path length in cm (0.2 cm). The CD absorbance was multiplied by 32.98 
(correlation coefficient) in order to be converted to θ (Woody, 1996; Kelly & Price, 2000). 
The buffer (10 mM sodium acetate, pH 5.0,) blank was subtracted from the C-SA PR data. 
The data were smoothed using SigmaPlot
®
 v 11.0. The smoothing of the data was done using 
SigmaPlot
®
 v 11.0 with a negative exponential smoothing technique. Accordingly, smoothing 
the data with a polynomial regression and weights computed from the Gaussian density 
function with a sampling proportion of 0.1. 
The change in structure could also be used to determine structural modifications upon 
binding of ligands to the proteases. However, signal-to-noise ratio is very low due to the 
presence of DMSO used to solubilise the highly insoluble protease inhibitors. Samples 
containing DMSO produced excessive noise (data not shown). 
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W6 
Figure 12: Crystal structure of C-SA PR (PDB I.D. 3U71) displaying secondary 
structural elements and fluorophores. 
Secondary structural elements: Β-sheets (yellow), α-helices (red), random coils (green). 
Fluorophores: W6 and W42 (orange) are solvent exposed. Y59 protrudes through the flap of 
the protease. Figure produced using PyMOL v0.99 (DeLano, 2002). 
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3.16 Tertiary structure characterisation – intrinsic fluorescence 
Aromatic compounds are optically active. They absorb light in the UV region at a wavelength 
characteristic of the compound. The absorbance process mitigates the transition of electrons 
into excited states. Fluorescence emission is the phenomenon of photon release upon the 
return of excited electrons to the ground state. The emission wavelength is longer than the 
excitation/ absorption wavelength. That is because the energy is lost to the solvent 
uponemission, producing a red shift (Lakowicz, 2006). 
Proteins contain several intrinsic fluorophores. The fluorophores most commonly excited are 
tyrosine and tryptophan at 280 nm and 295 nm, respectively. Fluorescence spectra provide 
information regarding the location of fluorophores on proteins. That is, solvent-exposed 
fluorophores lose energy to the solvent. As a result, the emission wavelength undergoes a red 
shift. Moreover, the presence of quenchers can be confirmed by quantifying the change in 
emission intensity after the addition of a quencher. A quencher can be a mutated amino acid 
as well (Royer, 1995; Lakowicz, 2006).  
There are two tryptophan residues and one tyrosine residue conserved in the C-SA PR and 
E35D↑G↑S. Namely, W6, W42 and Y59. The two tryptophan residues are completely 
exposed to the solvent while the tyrosine residue protrudes through the flap of the protease 
(Figure 12). The double insertion found in E35D↑G↑S may further expose Y59 to solvent and 
may cause a red shift in the emission spectra. However, the shift may not be prominent; thus, 
the fluorescence spectra of the two protease variants may not be different. Fluorescence 
spectroscopy can be used to determine the relative structural differences between C-SA PR 
and E35D↑G↑S. 
Fluorescence spectra were generated at 280 nm and 295 nm using the Jasco FP-6300 
Spectrofluorometer. The experimental parameters were set as follows: the excitation and 
emission bandwidths were 2.5 nm and 5 nm, respectively. The emission spectrum was 
measured from five accumulations using a data pitch of 0.5 nm and a scanning speed of  
200 nm/ min. The concentration of C-SA PR used was 5 µM. The data were plotted using 
Microsoft
®
 Office Excel 2010. 
3.17 Fluorometrically determined enzyme kinetics of C-SA PR 
The kinetic profile of C-SA PR was determined fluorometrically using a Jasco FP-6300 
Spectrofluorometer. The substrate, Abz-Arg-Val-Nle-Phe(NO2)-Glu-Ala-Nle-NH2, which 
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harbours a sequence preferred by HIV-1 proteases (Polgar et al., 1994), was used to 
determine the enzyme kinetics of C-SA PR. The substrate mimics the capsid/ p2 cleavage site 
found within the HIV-1 polyprotein chain. The sequence is recognised and hydrolysed 
between Nle (norleucine) and Phe(NO2) (nitro-phenylalanine) by the aspartic protease 
(Carmel & Yaron, 1978). The aminobenzoic acid (Abz) is excited at 337 nm and emits at 425 
nm; however, it is quenched by the proximal nitro-phenylalanine. Thus, time-dependent 
cleavage of the scissile peptide bond (product formation) can be monitored fluorometrically 
and used to determine the catalytic rates of HIV-1 protease variants. This method can also 
serve as a basic comparative study involving the activity and affinity of different HIV-1 
protease variants for this particular substrate. Of course, the kinetic parameters obtained are 
specific to the fluorogenic substrate used and to the sequence it mimics. To establish a 
dependence of substrate-sequence effects on HIV-1 protease affinity and activity, a broader 
study was performed involving various substrates (Polgar et al., 1994).  
Fluorescence intensity standards were done in triplicate using 1.25 nanomoles of completely 
cleaved substrate, allowing for the conversion of intensity units to amounts of fluorogenic 
substrate cleaved over time. The excitation and emission bandwidth for all kinetic 
experiments were 2.5 nm and 5 nm, respectively. The experiments were monitored using a 
medium sensitivity with a 0.5 s response and a 1 s data pitch. The activity buffer contained  
1 M NaCl and 100 mM sodium acetate, pH 5.00. The reaction volume was always kept 
constant at 400 μl. Cleavage rates were converted to appropriate units for each experiment. 
All experiments were performed in triplicate. 
3.17.1 Michaelis-Menten determination of KM for C-SA PR 
For a Michaelis-Menten plot to be produced, the concentration of substrate must span a broad 
range. The substrate concentrations used were 0, 5, 10, 25, 50, 100, 125, 150 and 200 μM. 
The enzyme was added last to a final concentration of 10 nM. Thereafter, the reaction was 
monitored at 337 nm for 30 s. The enzymatic activity (µmol.min
-1
) was plotted versus the 
concentration of substrate used (μM). The hyperbolic curve was fitted with the Michaelis-
Menten equation (Johnson & Goody, 2011; Briggs & Haldane, 1925) (equation 4) using  
SigmaPlot
®
 v 11.0: 
 
    
        
      
                                                                                                          (equation 4)  
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Where v0 is the initial velocity (before any significant amount of product is formed), Vmax is 
the maximum velocity of the enzyme, [S] is the concentration of substrate and, KM is the 
Michaelis-Menten substrate dissociation constant. The KM corresponds to the concentration 
of substrate that induces the enzyme to have half maximal velocity. KM can be used to 
identify whether the mutations and insertions in E35D↑G↑S alter the affinity of the 
fluorogenic substrate (and capsid/ p2 cleavage site) for the enzyme. Importantly, the KM value 
is needed for the design of specific activity/ catalytic turnover and, catalytic efficiency 
experiments.  
3.17.2 Determination of specific activity and catalytic turnover (kcat) of C-SA PR 
Specific activity is the catalytic activity of an enzyme standardised per milligram of enzyme. 
Data for specific activity can be used to determine the catalytic turnover of an enzyme. The 
catalytic turnover of an enzyme is the number of completed catalytic cycles by an active site 
per second (s
-1
). In order for specific activity and catalytic turnover to be determined, the 
enzyme must be saturated with substrate. Thus, allowing for the steady-state assumption to be 
made. The steady-state assumption dictates that all the enzymes in a solution are complexed 
with substrate at any given time. This assumption implies that the loss of enzyme-substrate 
complex is instantly countered by the formation of the complex. Moreover, the assumption 
that the formation of product is negligible is also made so that the factor of product inhibition 
can be eliminated (Segel, 1988). As a result, the initial velocity is equal to the maximum 
velocity which becomes a function of enzyme-substrate complex concentration and the 
turnover number. The catalytic turnover is calculated using equation 5. 
v0 = Vmax = kcat[ES]                                                                                                   (equation 5) 
Where v0 is the initial velocity, Vmax is the maximum velocity, kcat is the catalytic turnover 
and, [ES] is the total concentration of enzyme (assumed to be complexed with substrate). 
Therefore, the turnover number can be determined as long as either the substrate depletion or 
product formation can be monitored. In this case the formation of product was monitored 
fluorometrically (described in section 3.15). 
The substrate concentration was kept constant at 50 µM (steady-state). Enzyme was added 
last, in increasing increments of concentrations (10, 20, 30, 40 and 50 nM). The initial 
velocity (μmoles.min-1) was plotted against the amount of C-SA PR in milligrams, producing 
a gradient equivalent to the specific activity of C-SA PR (μmoles.min-1.mg-1). In order to 
determine kcat, the initial velocity (μmoles.s
-1
) was plotted against the amount of C-SA PR in 
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μmoles. The data were fitted using a linear equation resulting in a gradient equal to the 
catalytic turnover of C-SA PR (s
-1
). The data were fitted using SigmaPlot
®
 v 11.0. 
3.17.3 Determination of catalytic efficiency (kcat/ KM) of C-SA PR 
The catalytic efficiency of enzyme isoforms for a particular substrate is equated as a ratio of 
the turnover number (kcat) to the Michaelis-Menten substrate dissociation constant (KM). This 
proportion incorporates the affinity of enzymes for substrate (KM) as well as the rate of 
product released (kcat). The catalytic efficiency is directly used to compare the effectiveness 
of enzymes to catalyse the same substrate (Eisenthal et al., 2007).  
The catalytic efficiency or, specificity constant (kcat/ KM) cannot be calculated as a proportion 
of the independently determined kcat and KM values. That is because it is usually not the case 
for the catalysis of substrate to be limited only by the diffusion of the substrate. There are 
other factors such as conformational changes, solvent effects and free-energy barriers that 
contribute to the rate limiting step of substrate catalysis (Kuo-Chen, 1976; for review see Lin 
& Lapointe, 2013). As a result, the catalytic efficiency of enzymes is determined 
experimentally.  
Experimental determination of kcat/ KM is performed with concentrations of substrate 
significantly lower than the KM so that the rate of formation of the enzyme-substrate complex 
is accounted for. The concentration of enzyme was kept constant at 50 nM while the 
concentration of substrate was ranged from 2 µM to 8 µM at 1 µM intervals. Data were fitted 
as catalytic turnover (s
-1
) versus the concentration of substrate with a linear equation using 
SigmaPlot
®
 v 11.0. The gradient of the fit was equal to the enzyme-substrate specificity 
constant (s
-1
.µM
-1
).    
3.17.4 IC50 determination and calculation of Ki  
The concentration of protease inhibitor that effectively inhibits 50% of the enzyme (IC50) was 
determined separately for atazanavir, ritonavir and darunavir in the presence of 50 nM active 
enzyme and 50 μM fluorogenic substrate (saturating conditions, steady-state assumption). 
The concentrations of atazanavir and ritonavir used were: 0, 20, 25, 40, 50, 75, 150 and 200 
nM. The concentrations of darunavir used were optimised to accommodate for the stronger 
inhibitory ability of the inhibitor. The concentrations of darunavir used were: 0, 5, 10, 20, 25, 
40, 50, 75, and 100 nM.  
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The enzyme was pre-incubated with inhibitor for 1 hour. The substrate was added last to 
initiate the reaction. The reaction was monitored over thirty seconds. The buffer used was 
100 mM sodium acetate buffer, pH 5.00, containing 1 M NaCl and 2% DMSO. The IC50 
experiments were done in triplicate. Each singlet data set was fitted independently to 
determine the IC50 value, thus, enabling the production of a standard deviation from the 
triplicates. The triplicate plot was used to determine IC50 values. Data were fitted with a two-
parameter exponential decay model using SigmaPlot
®
 v 11.0. 
Obtained IC50 values and standard deviations were used to calculate Ki and the standard 
deviation of the determined Ki value. The Ki was calculated according to equation 6. 
   (      
   
 
)   (
   
  
  )                                                        (equation 6) 
Where Ki is the dissociation constant of the enzyme-inhibitor complex, in the presence of 
substrate; [E] is the concentration of active enzyme (50 nM), [S] is the concentration of 
substrate (50 µM). KM is the Michaelis-Menten constant determined experimentally 
(described in section 3.15.1) and IC50 is the concentration of inhibitor reducing the activity of 
the enzyme to 50%. IC50 was determined experimentally for atazanavir, ritonavir and 
darunavir. Equation 6 was developed for tight binding inhibitors (Copeland et al., 1995).  
Irreversible binders may have IC50 values equal to half of the concentration of enzyme. The 
concentration of reversible inhibitors should exceed half the concentration of the enzyme by a 
factor relative to the Ki of the inhibitor. Indeed, the stronger the binder, the lower the Ki value; 
therefore, lower concentration of inhibitor is needed to achieve IC50. 
The calculation of Ki requires the accurate determination of KM and IC50 values. The Ki value 
of inhibitors can also be determined accurately using the Dixon method (Dixon, 1953). 
However, this method requires the production of Michaelis-Menten plots using multiple 
concentrations of inhibitor. The plots would then be analysed using the Lineweaver-Burk 
method. However, this method is very expensive with respect to substrate. As a result, the 
Dixon method was not feasible considering the limited quantities of substrate available. 
3.18 Crystallisation trials  
Crystallisation trials were performed on both C-SA PR and E35D↑G↑S using the Hampton® 
screening kit. Crystal trials were set up using the hanging-drop vapour diffusion method.  
Crystallisation droplets were composed of equal volumes of protein solution and screening 
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solution. The final volume of the crystallisation droplets were 2 µl and 4 µl. Crystal trials 
were set with apo-enzymes and drug-complexed enzymes. The concentrations of enzyme 
used were 6 mg/ ml and 9 mg/ ml. The enzymes were prepared in a 10 mM sodium acetate 
buffer, pH 5.00, containing 0.02% sodium azide, prior to mixing equal volumes with the 
Hampton
®
 screening kit reagents. Crystal trials were set with C-SA PR with the aim to obtain 
a structure of a higher resolution than the 3U71 structure available. Lyophilised E35D↑G↑S 
was set up for crystallisation trials because a crystal structure contains highly valuable 
information. Although the lyophilised E35D↑G↑S sample contained contaminating peptides, 
the lack of any other sample has limited the options for crystal trials to this sample. 
4 Results 
4.1 Solubilisation of lyophilised E35D↑G↑S and confirmation of activity 
Lyophilised E35D↑G↑S was refolded by removing denaturants (6 M guanidinum 
hydrochloride and 8 M urea in the presence of 2 mM DTT) using dialysis. The pre- and post- 
dialysis samples were electrophoresed on a 10% polyacrylamide gel. The lyophilised sample 
of protease contained an unknown protein/ peptide contaminant with a molecular weight 
lower than 10 kDa as seen in lanes 1, 2, 3 and, 4 (Figure 13). Following overnight dialysis, 
autocatalysis was apparent as the amount of E35D↑G↑S decreased significantly (lanes 2 and 
4, Figure 13). 
A degradation study was set up in order to identify an optimal time for dialysis-assisted 
refolding that would produce refolded, active E35D↑G↑S within a minimum time period to 
limit autocatalysis. The time allocated for dialysis-assisted refolding was monitored with the 
aid of SDS-PAGE at various times over a 24-hour period. Densitometry analyses were 
performed on the electrophoresed gels. Bands typical of autocatalytic degradation emerged 
after 45 minutes of dialysis (Figure 14 A and B). An optimal dialysis period of 1 hour and 15 
minutes was chosen. 
The denatured sample of E35D↑G↑S was dialysed out of 8 M urea and 2 mM DTT for 1 hour 
and 15 minutes. After dialysis, the protease was shown to hydrolyse the fluorogenic substrate, 
confirming that the protease was active for further experiments (data not shown). 
Furthermore, as indicated by a 16% polyacrylamide gel (Figure 15), the protease was 
refolded and active since prominent bands of lower molecular weight than the E35D↑G↑S  
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Figure 13: Contaminated lyophilised E35D↑G↑S and autocatalysis of the refolded 
protease.  
E35D↑G↑S was dialysed overnight from different denaturants: Lane 1 shows E35D↑G↑S 
unfolded in 6 M guanidinium hydrochloride and 2 mM DTT; following dialysis-assisted 
refolding from 6 M guanidinium hydrochloride (lane 2). Lane 3 shows E35D↑G↑S unfolded 
in 8 M urea and 2 mM DTT; following dialysis-assisted refolding from 8 M urea (lane 4). 
The gel contained 10% polyacrylamide. Contaminating protein/ peptide present in the 
lyophilised sample (lanes 1, 2, 3 and, 4) indicated by the arrow. 
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Figure 14: Degradation trial of lyophilised E35D↑G↑S  
(A) The E35D↑G↑S protease, electrophoresed on a 16% polyacrylamide gel, autocatalyses 
rapidly. Bands of lower molecular weight than 10 kDa, characteristic of autocatalysis, 
emerged after 45 minutes of dialysis (indicated by a black arrow). (B) Densitometry analyses 
were performed on the 16% polyacrylamide gel using GelAnalyzer. The densitometry 
intensity points were fitted with Sigma Plot
®
 11.0.  
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Figure 15: Refolding of lyophilised E35D↑G↑S 
E35D↑G↑S was refolded via dialysis (for 1 hour and 15 minutes) from 8 M urea and 2 mM 
DTT (10 mM Tris-HCl buffer, pH 8.00) (lane 1) into 10 mM sodium acetate buffer, pH 5.00, 
containing 0.02% sodium azide (lane 2). Prominent bands of lower molecular weight than 10 
kDa emerged (characteristic of autocatalysis), indicating that the E35D↑G↑S protease was 
successfully refolded and activated. 
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protease emerged – a phenomenon typical of autocatalysis. The refolded E35D↑G↑S was 
titrated with acetyl-pepstatin in order to determine the percentage of active protease (Figure 
16). The titration did not reach saturation as expected. The thermal signals for the injections 
were endothermic (ΔH > 0). 
4.2 Expression trials of E35D↑G↑S in Escherichia coli BL21(DE3)pLysS cells at 
20 ˚C and 37 ˚C 
Expression trials of E35D↑G↑S were set up using E. coli BL21(DE3)pLysS cells at 20 ˚C 
(Figure 17 A) and 37 ˚C (Figure 17 B). Varying concentrations of IPTG and induction 
periods were tested. Induction was done at O.D.600 = 0.6 (mid-log phase of growth curve). 
The media used was LB-Lennox. Overexpression was not observed in either the soluble 
fraction or the pelleted insoluble fraction. 
4.3 Expression trials of the inactive mutant E35D↑G↑S D25A in E. coli 
BL21(DE3)pLysS and E. coli Rosetta 2
®
 cells 
Expression trials of E35D↑G↑S D25A were performed using E. coli BL21(DE3)pLysS 
(Figure 18) and E. coli Rosetta 2
®
 (Figure 19 A) cells at 37 ˚C in LB-Lennox. Additionally, 
expression trials using E. coli Rosetta 2
®
 cells were performed using LB-Miller (Figure 19 
B). Induction was done at an O.D.600 = 0.6 with various concentrations of IPTG. The 
induction period was also varied. Overexpression of the E35D↑G↑S D25A protein was not 
detectable in either the soluble or the pelleted insoluble fractions. 
4.4 Pre-modified purification of C-SA PR 
C-SA PR was expressed as inclusion bodies. The refolded protease was purified using CM-
sepharose cation exchange chromatography (Figure 20 A). When the protease was activated 
via dialysis from refolding buffer (10 % glycerol) into 10 mM sodium acetate buffer, pH 
5.00, containing 0.02% sodium azide, without 2 mM NaCl and 2 mM DTT, the eluted 
protease sample was contaminated with a protein of ~15 kDa. Moreover, autocatalysis 
products below 10 kDa were also present in the sample (Figure 20 B). The purified C-SA PR 
sample was shown to contain contaminating proteins/ peptides using UFLC chromatography 
(Figure 21). Moreover, the C-SA PR peak contributes 56% to the sum total intensity of the 
identified peaks in the UFLC chromatogram. The protease sample was titrated with acetyl-  
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Figure 16: Active site titration of refolded E35D↑G↑S with acetyl-pepstatin  
(A) E35D↑G↑S was titrated with acetyl-pepstatin. The titration did not reach saturation. 
Thermal injections were endothermic. The data were fitted with a one-to-one fitting model 
using NanoAnalyze (TA Instruments). (B) The thermodynamic parameters of the active site 
titration are outlined. 
 
B 
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Figure 17: Expression trials of E35D↑G↑S in E. coli BL21(DE3)pLysS at (A) 20 ˚C and 
(B) 37 ˚C at varying concentrations of IPTG and induction periods in LB-Lennox 
Expression of E35D↑G↑S was induced at O.D.600 = 0.6 with various concentrations of IPTG 
for 4 hours, 6 hours and overnight. C-SA PR was electrophoresed as a molecular weight 
marker indicating accurately where E35D↑G↑S should be expected. Overexpression was not 
observed in either the soluble supernatant (S) or in the insoluble pellet (P). 
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Figure 18: Expression trials of E35D↑G↑S D25A in E. coli BL21(DE3)pLysS at 37 ˚C in 
LB-Lennox using various concentrations of IPTG and induction periods 
E35D↑G↑S D25A is an inactive variant of the E35D↑G↑S protease. Overexpression of 
E35D↑G↑S D25A was induced at O.D.600 = 0.6 with various concentrations of IPTG for 4 
hours, 6 hours and overnight. C-SA PR was electrophoresed as a molecular weight marker 
indicating accurately where E35D↑G↑S should be expected. Overexpression was not 
observed in the soluble supernatant (S) or in the insoluble pellet (P).  
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Figure 19: Expression trials of E35D↑G↑S D25A in E. coli Rosetta 2® cells in (A)  
LB-Lennox and (B) LB-Miller 
Overexpression of the inactive protease variant E35D↑G↑S D25A was induced at O.D.600 = 
0.6 with various concentrations of IPTG for 4 hours, 6 hours and overnight. C-SA PR was 
electrophoresed as a molecular weight marker indicating accurately where E35D↑G↑S should 
be expected. Overexpression was not observed in either the soluble supernatant (S) or in the 
insoluble pellet (P). Feint S lanes indicate insufficient proteins in the soluble fraction. 
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Figure 20: (A) Elution and (B) purification profile of C-SA PR using pre-modified 
protocol 
C-SA PR was activated via dialysis into 10 mM sodium acetate buffer, pH 5.00, containing 
0.02% sodium azide, without 2 mM NaCl and 2 mM DTT. The eluted protease sample 
contains contaminating proteins and autocatalysis products (concentrated C-SA PR).  
(A) Fractions were eluted from a CM-sepharose column using a NaCl gradient.  (B) Eluted 
fractions were electrophoresed on 16% polyacrylamide gel. 
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Figure 21: UFLC chromatogram of purified C-SA PR  
The concentrated C-SA PR was analysed using UFLC. The protease was activated via 
dialysis into 10 mM sodium acetate buffer, pH 5.00, containing 0.02% sodium azide, without 
2 mM NaCl and 2 mM DTT. Contaminating protein peaks are indicated by arrows. The  
C-SA PR peak contributes 56% to the sum total intensity of the identified peaks. 
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pepstatin in an active site titration experiment and was determined that 55% of the C-SA PR 
protease sample was active (Figure 22 A and B). 
4.5 Modified purification of C-SA PR 
C-SA PR was eluted from a CM-sepharose column with an approximate 380 mM 
concentration of NaCl (Figure 23 A and B). The purification profile is similar to the one 
obtained for the pre-modified protocol. However, the protease sample obtained did not 
contain the contaminants that were present when using the pre-modified protocol as can be 
observed on SDS-PAGE and HPLC (Figure 24 A and B). However, there is a protein band 
immediately above the C-SA PR band that could be contaminant, or C-SA PR that did not 
autoprocess out of the gag-pol recognition sequence (Figure 24 A). The C-SA PR peak 
contributes 69% to the sum total intensity of the identified peaks in the UFLC chromatogram 
(Figure 24 B). In addition, the concentration of active C-SA PR was 74% when using the 
modified protocol, as determined with an active site titration of C-SA PR with acetyl-
pepstatin (Figure 25). The activation of the protease in 10 mM sodium acetate buffer, pH 
5.00, containing 0.02% sodium azide, 2 mM DTT and 2 mM NaCl yields a higher percentage 
of active C-SA PR. 
4.6 Structural characterisation of C-SA PR 
4.6.1 Far-UV circular dichroism – secondary structural characterisation 
The far-UV CD mean residue ellipticity spectrum of C-SA PR (Figure 26) had a trough at  
216 nm and a peak at 203.5 nm. The far-UV CD spectrum of C-SA PR indicates that the 
protein is predominantly β sheeted with a high proportion of random coils (Kelly & Price, 
2000). The data in Figure 26 were smoothed using SigmaPlot
®
 v 11.0. Data smoothing was 
done using the negative exponential smoothing technique which is a local smoothing 
technique using polynomial regression and weights computed from the Gaussian density 
function. 
4.6.2 Intrinsic fluorescence – tertiary and quaternary structural characterisation 
Excitation of C-SA PR at 280 nm and 295 nm wavelengths resulted in emission peaks at  
346 nm in both instances (Figure 27). The fluorescence intensity is approximately 3 times 
higher when exciting at 280 nm when compared to exciting at 295 nm. The data were plotted 
using Microsoft
®
 Excel 2010. 
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Figure 22: Active-site titration with acetyl-pepstatin against C-SA PR 
(A) The C-SA PR purified using the pre-modified purification protocol was titrated with 
acetyl-pepstatin. The binding parameters of the titration are outlined in B. The parameters are 
as expected for the titration. The stoichiometry is 55%. Data were fitted with a one-to-one 
fitting model using NanoAnalyze (TA Instruments). The errors of the thermodynamic 
parameters are a direct resultant of the standard deviation of the fit (1.00). 
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Figure 23: Elution profile of C-SA PR using modified purification protocol  
(A) Elution chromatogram of C-SA PR and (B) 16% polyacrylamide gel of chromatographed 
components. C-SA PR was activated via dialysis into 10 mM sodium acetate buffer, pH 5.00, 
containing 0.02% sodium azide, 2 mM NaCl and 2 mM DTT. The purification flow-through 
contained proteins co-precipitated with the protease when overexpressed. The first eluent 
contained autocatalysis products. The second eluent contained mostly C-SA PR. The band 
above C-SA PR could be either contaminating protein unable to be removed using CM-
sepharose or C-SA PR with the gag-pol recognition sequence that may not have been cleaved 
off yet. 
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Figure 24: Purification profile of C-SA PR using modified purification protocol 
(A) 16% polyacrylamide gel and (B) UFLC chromatogram of purified C-SA PR sample 
activated via dialysis into 10 mM sodium acetate buffer, pH 5.00, containing 0.02% sodium 
azide, 2 mM NaCl and 2 mM DTT. The electrophoresed band above C-SA PR could be either 
contaminating protein that were not removed during the purification or C-SA PR with the 
gag-pol recognition sequence that may not have been cleaved off yet. Contaminating protein 
peaks are indicated by arrows. C-SA PR contributes 69.0% to the total intensity of the UFLC 
chromatogram.  
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Figure 25: Active-site titration with acetyl-pepstatin against C-SA PR  
The C-SA PR sample used in this titration (A) was purified using modified purification 
protocol. The binding parameters of the titration are outlined in B. The stoichiometry is 74%. 
Data was fitted with a one-to-one fitting model using NanoAnalyze (TA Instruments). The 
errors of the thermodynamic parameters are a direct resultant of the standard deviation of the 
fit (0.87).  
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Figure 26: Far-UV circular-dichroism spectra of C-SA PR 
The mean residue ellipticity of the far-UV CD spectrum of C-SA PR has a trough at 216 nm 
and a peak at 203.5 nm. The trough at 216 nm indicates that the protein contains a large 
proportion of β sheets. The peak at 203.5 further confirms that the protein is β-sheeted. 
However, the peak at 203.5 nm is typical of β-sheeted proteins with a high content of random 
coils. The data was fitted and smoothed with SigmaPlot
®
 v 11.0. The data were smoothed 
using the negative exponential smoothing technique which is a local smoothing technique 
using polynomial regression and weights computed from the Gaussian density function. 
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Figure 27: Intrinsic fluorescence of C-SA PR 
C-SA PR was excited at 280 nm and 295 nm. The emission maximum is at 346 nm at both 
excitation wavelengths. Excitation at 280 nm produces an emission signal 3 times higher than 
excitation at 295 nm. Data were plotted using Microsoft
® 
Excel 2010. 
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4.7 Enzyme kinetics of C-SA PR 
4.7.1 Michaelis-Menten KM determination  
The dissociation constant (KM) of the fluorogenic substrate, resembling the capsid/ p2 
cleavage site, from C-SA PR was determined to be 20.22 ±4.09 µM. The data were fitted 
using SigmaPlot
®
 v 11.0 with the Michaelis-Menten equation. The KM was obtained from the 
equation of the plot (Figure 28). The correlation coefficient (R
2
) of the fitted data fit was 
0.97. 
4.7.2 Specific activity and catalytic turnover 
The specific activity and catalytic turnover of C-SA PR were determined from the same data 
set under steady-state conditions (enzyme saturated with substrate). However, the units were 
converted accordingly. The specific activity of C-SA PR was determined to be  
35.68 ±1.06 µmoles.min
-1
.mg
-1 
(Figure 29 A) and the catalytic turnover, kcat = 12.79 ±0.38 s
-1
 
(Figure 29 B). Data were fitted linearly using SigmaPlot® v 11.0. The correlation coefficient 
of the fitted data set was R
2
 = 0.99. 
4.7.3 Catalytic efficiency of C-SA PR 
The catalytic efficiency/ specificity constant (kcat.KM
-1
) of C-SA PR for the fluorogenic 
substrate and, therefore, for the capsid/ p2 cleavage site was determined under non-steady-
state conditions (S << KM). The data were plotted as catalytic turnover against substrate 
concentration and fitted linearly using SigmaPlot
®
 v 11.0. The catalytic efficiency of the 
reaction was determined to be 1.17 ±0.06 s
-1
.μM-1 (Figure 30). The correlation coefficient of 
the data fitting was R
2
 = 0.98.  
4.8 Inhibition kinetics of atazanavir, ritonavir and darunavir against C-SA PR 
The inhibitor concentration that inhibits 50% of the enzyme (IC50) is specific to the 
experimental conditions used, with particular regards to the enzyme concentration (50 nM). 
However, the concentration of substrate (50 µM) is equally important. The enzyme-substrate 
complex dissociation constant in the presence of substrate (Ki) was calculated from the IC50 
values obtained for atazanavir, ritonavir and, darunavir using equation 6. 
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Figure 28: Michaelis-Menten plot of the hydrolysis of fluorogenic substrate catalysed by 
C-SA PR 
The data was fitted with the Michaelis-Menten equation using SigmaPlot
® 
v 11.0. The 
correlation coefficient of the fit was R
2
 =0.97. The KM was determined from the Michaelis-
Menten equation. KM = 20.22 ±4.09 µM. The error bars are standard deviation values 
obtained from the experiment performed in triplicate. 
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Figure 29: (A) specific activity and (B) catalytic turnover of C-SA PR 
The plots were generated using the same data points. However, the units were converted so 
that the gradient of each plot gives specific activity and kcat, respectively. The goodness of fit 
is R
2
 = 0.99 for both plots. The specific activity of C-SA PR was determined experimentally 
to be 35.68 ±1.06 µmoles.min
-1
.mg
-1
. Likewise, the catalytic turnover of C-SA PR was 
determined to be kcat = 12.79 ±0.38 s
-1
. The error bars are standard deviation values obtained 
from the experiment performed in triplicate. 
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Figure 30: Catalytic efficiency of C-SA PR 
The catalytic efficiency/ specificity constant of C-SA PR for the fluorogenic substrate which 
mimics the capsid/ p2 cleavage site was determined to be kcat.KM
-1
 = 1.17 ±0.06 s
-1
.μM-1. The 
correlation coefficient of the fit was R
2
 = 0.98. Data were fitted with a linear fit using 
SigmaPlot
® 
v 11.0. The gradient of the fit is equal to the catalytic efficiency. The error bars 
are standard deviation values obtained from the experiment performed in triplicate. 
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The fitted data sets for the IC50 determination of atazanavir, ritonavir and darunavir are 
displayed in Figure 31 A, B and C, respectively. The correlation coefficients of the data sets 
of atazanavir, ritonavir and darunavir were R
2
 = 0.99, 0.98 and 0.98, respectively. The IC50 
values were determined in triplicate. Data were fitted with a two-parameter exponential decay 
model using SigmaPlot
®
 v 11.0. The error bars are standard deviation values obtained from 
the experiment performed in triplicate. 
The IC50 values of atazanavir, ritonavir and darunavir were determined to be  
54.63 ±12.60 nM, 49.63 ±9.85 nM and 25.99 ±0.13 nM, respectively. The calculated Ki 
values for atazanavir, ritonavir and darunavir were 8.53 ±2.06 nM, 7.09 ±2.84 nM and  
285.07 ±36.00 pM, respectively. The IC50 and Ki values of the three inhibitors are graphically 
represented in Figure 32. 
4.9 Thermodynamics of binding of atazanavir, ritonavir and darunavir to  
C-SA PR 
The energetics of binding of atazanavir, ritonavir and darunavir were determined in 
displacement-titration calorimetry experiments. The three inhibitors were titrated against  
C-SA PR complexed with acetyl-pepstatin. The thermograms of the displacement titrations 
are displayed in Figure 33. The standard deviation values of the data-fits were 1.83, 1.24 and 
1.50 for atazanavir, ritonavir and darunavir, respectively. The thermodynamics of binding of 
atazanavir, ritonavir and darunavir to C-SA PR are depicted and specified in Figure 34. 
Atazanavir and ritonavir have similar thermodynamic parameters as well as comparable 
dissociation constants in the pico-molar region. Atazanavir has a Kd of 160.56 ±54.59 pM and 
ritonavir has a Kd of 113.34 ±46.47 pM. The binding of the two inhibitors to C-SA PR is 
enthalpically unfavourable. Darunavir binds tighter than atazanavir and ritonavir, having a 
dissociation constant, Kd = 10.24 ±6.02 pM. The binding of darunavir is also enthalpically 
favourable. Darunavir has the lowest dissociation constant, in the low pico-molar region. The 
data were fitted using NanoAnalyze (TA Instruments).  
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Figure 31: IC50 determination of (A) atzanavir, (B) ritonavir and (C) darunavir for  
C-SA PR 
The correlation coefficient of the data sets, were 0.99, 0.98 and 0.98, for atazanavir, ritonavir 
and darunavir, respectively. Data was fitted with a two parameter exponential decay model 
using SigmaPlot
®
 v 11.0. The error bars are standard deviation values obtained from the 
experiment performed in triplicate. 
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Figure 32: Graphical representation of the IC50 and Ki values of atazanavir, ritonavir 
and darunavir for C-SA PR 
Atazanavir and ritonavir have comparable inhibitory potencies. However, ritonavir is a 
stronger inhibitor of C-SA PR than atazanavir. Darunavir inhibits C-SA PR with the highest 
potency between the three inhibitors. The binding of darunavir is significantly tighter, having 
an IC50 values close to 25 (value expected for irreversible inhibitors). The error bars are 
standard deviation values obtained from the experiments performed in triplicate. The graph 
was produced using Microsoft
®
 Office Excel 2010. 
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Figure 34: Thermodynamics of binding of atazanavir, ritonavir and darunavir to  
C-SA PR 
Atazanavir and ritonavir have similar binding energetics. However, darunavir binds tighter 
than atazanavir and ritonavir. In addition, the binding of darunavir to C-SA PR is 
enthalpically favourable, as opposed to atazanavir and ritonavir. The units of ΔG, ΔH and  
-TΔS are in kJ.mol-1. The dissociation constant, Kd, is standardised in pM units. Data was 
fitted with NanoAnalyze. The error bars are resultant of the standard deviations of fit. The 
graph was produced using Microsoft
®
 Office Excel 2010. 
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5 Discussion 
5.1 Solubilisation of lyophilised E35D↑G↑S and confirmation of activity 
E35D↑G↑S is a naturally occurring double insertion variant of C-SA PR. Chemical synthesis 
is an alternate and viable option of obtaining proteins that may prove problematic to express 
in biological systems (Nillson et al., 2005). A chemically synthesised, lyophilised sample of 
E35D↑G↑S was obtained. The lyophilised E35D↑G↑S sample contained smaller peptides; 
this is not uncommon for chemically synthesised amino-acid chains (Mueller et al., 2012). 
The protease seemed to be prone to autocatalysis since most of the sample appeared to have 
been degraded after overnight dialysis-assisted refolding (Figure 13; Figure 14 and Figure 
15). Some of the lyophilised E35D↑G↑S was active after 30 minutes of dialysis since 
electrophoresed protein bands, typical of autocatalysis, were observed (Figure 14 A and 
Figure 14). Figure 14 B is representative of the proteolytic autocatalysis exhibited by the 
E35D↑G↑S protease. Although the correlation co-efficient of the data fit in Figure 14 B is 
only 0.93, it is clear that autocatalysis occurs upon refolding of the protease.  
The Q7K autocatalysis-resistant mutation was present in both C-SA PR and E35D↑G↑S 
protease variants. However, there are two other mutations (L33I and L63I) that have been 
shown to prevent autocatalysis (Mildner et al., 1994). These mutations were not incorporated 
into the protease sequences resulting in autocatalytic activity. It is recommended that the 
L33I and L63I mutations are introduced in the protease sequences before further 
experimentation. 
Reducing the period of dialysis-assisted refolding from overnight to just 1 hour and  
15 minutes at 4 °C, has afforded a decrease in the period allowed for autocatalysis. However, 
the E35D↑G↑S remained autocatalytically active as observed on the 16% polyacrylamide gel 
in Figure 15. Additionally, the experimental preparation of the active-site titration experiment 
(Figure 16) involved the thermal equilibration of the E35D↑G↑S sample to 20 °C. The 
thermal equilibration process was approximately 2 hours. Consequently, the protease may 
have been more prone to autocatalysis at the elevated temperature. As a result, the amount of 
active protease remaining in the sample cell may have been considerably reduced. Thus, the 
failure to reach saturation during the active site titration (Figure 16) may be an effect of the 
lack of active E35D↑G↑S. On the other hand, 1 hour and 15 minutes of dialysis may have 
been insufficient for the removal of residual urea. The solvation of urea in water is 
endothermic (Della Gatta et al., 2007). Residual urea may have contributed to the 
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endothermic signal of the active site titration, thus, interfering with the thermodynamic 
profile. Furthermore, the apparent entropically driven binding of acetyl-pepstatin to 
E35D↑G↑S (Figure 16), can be explained by the chaotropic properties of urea. The solvation 
of urea increases the entropy of the system (Moelbert, et al., 2004).  
5.2 Expression trials of E35D↑G↑S in Escherichia coli BL21(DE3)pLysS cells at 
20 ˚C and 37 ˚C 
Escherichia coli is a commonly used host for protein expression. E. coli has minimal 
requirements for growth, replicates rapidly and the genetic constitution of E. coli is well-
understood. Overexpression of proteins in E. coli is a preferred method of protein production 
as it is cost-effective and reproducible once conditions are established (Baneyx, 1999). The 
overexpression of E35D↑G↑S became an objective in this study due to the limited supply of 
the lyophilised E35D↑G↑S sample. The wild type variant, C-SA PR can be overexpressed 
and recovered from E. coli BL21(DE3)pLysS. Therefore, expression trials of the E35D↑G↑S 
protease were set up using E. coli BL21(DE3)pLysS cells. 
Expression trials of E35D↑G↑S were unsuccessful (Figure 17 A and B) since expression was 
not observed at varying temperatures (20 ºC and 37 ºC), concentrations of IPTG (0 - 1 mM) 
and induction periods (4 hours, 6 hours and overnight). It was speculated that overexpression 
was prevented by the autocatalytic and cytotoxic properties of the E35D↑G↑S protease. In 
order to verify that, an inactive E35D↑G↑S protease incorporating the active site mutation, 
D25A, was produced using site-directed mutagenesis. 
5.3 Expression trials of the inactive mutant E35D↑G↑S D25A in E. coli  
BL21(DE3)pLysS and E. coli Rosetta 2
® 
cells 
A D25A active site mutation was produced for both C-SA PR and E35D↑G↑S. Expression 
trials were only performed with the E35D↑G↑S D25A protease because E35D↑G↑S, unlike 
C-SA PR, did not overexpress. 
The aspartic acid residue at position 25 was selected for mutation because it is the catalytic 
residue responsible for the acid-base hydrolysis of the substrate. It has been shown that a 
D25N mutation in HIV-1 proteases impairs dimerisation (Sayer et al., 2008). Therefore, the 
aspartic acid at position 25 was substituted with an alanine residue. The D25A mutation 
inactivates HIV-1 proteases without affecting dimerisation (Koh et al., 2011).  
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Expression trials did not produce any detectable quantities of E35D↑G↑S D25A in E. coli 
BL21(DE3)pLysS at 37 ºC regardless of the IPTG concentrations and induction periods 
(Figure 18). Hence, it was deduced that the codons present in E. coli BL21(DE3)pLysS are 
not compatible with the E35D↑G↑S gene sequence used. Although C-SA PR does express, 
the gene sequence of C-SA PR was not codon harmonised with the expression host. Since 
E35D↑G↑S was designed using the C-SA PR gene sequence template, codon mismatches 
were inherent. Codon mismatches are known to hinder protein expression (Angov et al., 
2011).  For that reason, E. coli Rosetta 2
®
 cells were used in expression trials of E35D↑G↑S 
D25A as the Rosetta 2
®
 cell line contains seven rare codons. 
Overexpression of E35D↑G↑S D25A was not detected in Rosetta 2® cells (Figure 19 A and 
B). The lack of expression of the inactive E35D↑G↑S D25A protease reiterates the codon 
incompatibility of the E35D↑G↑S gene sequence with the expression host. The sequence of 
E35D↑G↑S ought to be harmonised with the expression host. Moreover, codon harmonisation 
may also improve the yield of both wild type C-SA PR and E35D↑G↑S variants recovered 
from expression hosts (Angov et al., 2011). 
5.4 Pre-modified purification of C-SA PR  
The wild type C-SA PR was refolded in 10% glycerol with 10 mM formic acid and 0.02% 
sodium azide. Contaminating cellular contents from the E. coli expression host precipitated 
when dialysed in activation buffer (10 mM sodium acetate, pH 5.00, containing 0.02% 
sodium azide). A significant amount of remaining contaminating proteins were eluted in the 
flow through using a CM-sepharose column (Figure 20 A and B). The NaCl continuous 
gradient used to elute C-SA PR removed a significant amount of a contaminant with a 
molecular weight of 15 kDa (Figure 20 A and B).  However, the eluted C-SA PR still 
contained some contaminating proteins, probably because of the similar charge of the 
contaminant allowing simultaneous binding and elution of the contaminant and C-SA PR 
from the CM-sepharose column. The gel displayed in Figure 20 B appears to have been 
overloaded with highly concentrated precipitated fraction in refolding buffer. The overloaded 
sample may have spilled over into neighbouring wells. Nevertheless, the UFLC 
chromatogram in Figure 21 confirms the presence of contaminating proteins. The identity of 
the contaminating proteins cannot be determined with the technique. However, a western blot 
analysis of SDS-PAGE gels could reveal if the contaminating protein is unprocessed PR from 
the gag-pol region or other protein contaminant.  
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The percentage contribution of the intensity of the peak labelled C-SA PR to the sum total of 
the intensities of all the peaks in the UFLC chromatogram (Figure 21) is 56%. This value is 
strikingly similar to the percentage of active sites in the same sample (~55%) determined 
calorimetrically with an active site titration (Figure 22 A and B). This correlation between the 
data sets confirms that acetyl-pepstatin does not bind non-specifically. Attesting further to 
this fact, are the similar thermodynamic parameters (ΔH = 38.1 kJ/ mol; Kd = 0.25 μM)   of 
the active site titration found in literature (Naicker et al., 2014). 
5.5 Modified purification of C-SA PR 
Activating C-SA PR in sodium acetate buffer, pH 5.00, containing 0.02% sodium azide, 
2mM DTT and 2 mM NaCl, allowed for the improved removal of contaminating proteins 
from the C-SA PR sample. The effect is observed when comparing the purification profile 
obtained using the modified protocol (Figure 23 and Figure 24) with the purification profile 
obtained using the pre-modified protocol (Figure 20 and Figure 21). A significant amount of 
contaminant has been eliminated using the modified protocol.  
The band immediately above the C-SA PR band in the “concentrated C-SA PR” lane in 
Figure 24 A, may be C-SA PR that has not been autocatalysed out of the gag-pol region of 
the recombinant protein, which may contribute to the percentage of active C-SA PR. This 
could be confirmed by performing a western blot analysis of gels revealing a similar profile. 
Alternatively, contaminant may be present. The contribution of C-SA PR to the sum total of 
the intensities of all the peaks in the UFLC chromatogram (Figure 24 B) is 69% which 
exceeds the 56% contribution when using the pre-modified purification protocol. In addition, 
the 69% contribution is close to the 74% active C-SA PR determined calorimetrically  
(Figure 25). This data further verifies that acetyl-pepstatin does not bind non-specifically. 
The use of DTT in the purification of C-SA PR has a beneficial effect. However, it is 
important that DTT is removed from samples prior to experimentation because HIV-1 
protease has been shown to have elevated catalytic activity in the presence of the reducing 
agent (Davis et al., 1999). The reason why the sample purified in the presence of DTT may 
yield protein of higher purity despite elevated autocatalytic activity conferred by DTT is as 
follows: Autocatalysed specimens in samples without DTT may be held together by the 
disulphide bonds created by the non-reduced cysteine residues, thus, retaining the isoelectric 
point of the protease and eluting together with the intact specimens from the CM-sepharose 
column. However, autocatalysed specimens will not be held together by disulphide bonds in 
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the presence of DTT, thus, their isoelectric points would change and would not elute together 
with the intact specimens from the CM-sepharose column. After purification, DTT is 
removed immediately through dialysis. Nevertheless, the mutation of the two conserved 
cysteine residues to alanine residues (C67A and C95A) may be cost effective by eliminating 
the need for a reducing agent. However, the C67A and C95A have been shown to increase 
the catalytic activity of HIV-1 protease by as high as 5 fold (Davis et al., 1999). Therefore, it 
may not be solely beneficial to introduce the C67A and C95A mutations as this may result in 
excessive use of substrate.  
5.6 Structural characterisation of C-SA PR 
5.6.1 Far-UV circular dichroism – secondary structural characterisation 
The far-UV CD spectra of C-SA PR reveals that the secondary structure of the protein is 
characteristically beta-sheeted (Woody, 1995; Mosebi et al., 2008; Corrêa & Ramos, 2009). 
More specifically, the trough at 216 nm (Figure 26) indicates that the beta strands form 
antiparallel beta sheets (Kelly & Price, 2000; Ishima et al., 2001; Frutos et al., 2007). The 
peak at 203.5 nm is somewhat out of the range of a beta sheeted profile. This is likely due to 
ellipticity contributed by the large proportion of random coils and the 4-amino-acid alpha 
helix in each monomer of C-SA PR (Kelly & Price, 2000). 
Considering the far-UV CD spectra characteristics, a thermal unfolding curve was produced 
using a 216 nm wavelength (data not shown). However, the signal-to-noise ratio was too low 
for the data to display a sigmoidal trend. This made the identification of an inflection point 
difficult. Therefore, the melting point (Tm) of the protein could not be determined with 
significant accuracy.  
5.6.2 Intrinsic fluorescence – tertiary and quaternary structural characterisation  
The fluorescence intensity emitted by C-SA PR (Figure 27) at 295 nm is lower than that 
emitted at 280 nm (both peaking at 346 nm). That is because at 280 nm, both the tyrosine and 
tryptophan residues are excited. Moreover, thermal unfolding studies should be performed 
exciting the sample at 280 nm because; firstly, the signal is more intense, and secondly, 
because all the tryptophan residues are already solvent-exposed while the tyrosine residue is 
partially covered by the flap of the protease (Figure 12). Therefore, a red shift in emission 
wavelength when exciting at 295 nm is unlikely. Moreover, a red shift in the emission 
wavelength when exciting at 280 nm may not be prominent; thus, the fluorescence spectra of 
the two protease variants may not be different. Due to the lack of a digitally regulated peltier, a 
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thermal unfolding study could not be performed using intrinsic fluorescence spectroscopy. 
The intrinsic fluorescence profile of C-SA PR could have been used to compare quaternary 
structural differences with E35D↑G↑S, if the fluorescence spectroscopy profile of E35D↑G↑S 
was obtained. 
5.7 Enzyme kinetics of C-SA PR 
The kinetic parameters of C-SA PR obtained experimentally in this study are comparable to 
the kinetic parameters of C-SA PR and subtype B PR found in literature using the same 
fluorogenic substrate (Naicker et al., 2013; Naicker et al., 2014) (Table 1). The KM, specific 
activity, kcat and kcat/ KM of C-SA PR determined in this study do not differ greatly from that 
of published studies with C-SA PR and subtype B PR using the same fluorogenic substrate. 
However, due to the lack of literature revolving around the fluorogenic substrate, it is 
difficult to conclude on the significance of the small differences between the data sets. 
Nevertheless, the accurate determination of KM is necessary in calculating the Ki of the 
inhibitors (Copeland et al., 1995). The KM, specific activity, kcat and kcat/ KM of C-SA PR 
(Figure 28, Figure 29 and Figure 30) would have been used to compare the affinity, 
specificity and catalytic activity of the C-SA PR and E35D↑G↑S protease variants for the 
capsid/ p2 cleavage site incorporated in the fluorogenic substrate. 
5.8 Inhibition kinetics of atazanavir, ritonavir and darunavir against C-SA PR 
The concentration of atazanavir, ritonavir and darunavir that reduces the activity of C-SA PR 
by 50% was determined (Figure 31 and Figure 32). The error of the IC50 values for atazanavir 
(~23%) and ritonavir (~20%) are relatively large. However, this is not uncommon when 
monitoring the cleavage of substrate fluorometrically. Experimental errors of fluorometrically 
determined IC50 values in literature have been noted to be ranging from 9% to 43% (Naicker 
et al., 2014). In addition, the Ki values of atazanavir, ritonavir and darunavir were calculated 
using equation 6. The errors of the Ki values are a consequence of the IC50 errors.  
Atazanavir and ritonavir have similar inhibitory potencies. However, darunavir is a 
significantly more potent C-SA PR inhibitor. This was also shown by the finding of Naicker 
et al., 2014 regarding both C-SA PR and subtype B PR (Naicker et al., 2014) (Table 1). 
Although the literature indicates that darunavir is a significantly more potent inhibitor of 
subtype B PR than of C-SA PR, this study indicates the contrary. Once again, the lack of 
literature in this are containing data generated using the same fluorogenic substrate does not 
allow for thorough comparisons to be made. However, it is certain that darunavir is the most  
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Table 2: Comparison of the kinetic parameters of C-SA PR obtained experimentally in 
this study with the kinetic parameters of C-SA PR and subtype B PR found in literature 
 
 
 
 
 
 
 
 
 
  
Experimentally 
determined in this 
study 
 
 
C-SA PR 
(Naicker et 
al., 2013) 
 
C-SA PR 
(Naicker et 
al., 2014) 
 
Subtype B PR 
(Naicker et al., 
2014) 
KM (μM) 
 
20.22 ±4.09 – 29.4 ±4.4 38.7 ±6.0 
Specific activity 
(μmoles.min-1.mg-1) 
 
35.68 ±1.06 79 – – 
kcat (s
-1
) 
 
12.79 ±0.38 – 20.6 ±0.8 9.0 ±0.2 
kcat/ KM (s
-1.μM-1) 
 
1.17 ±0.06 – 0.46 ±0.5 0.32 ±0.1 
ki ATV (nM) 
 
8.53 ±2.06 – 5.53 ±1.88 10.96 ± 4.29 
ki RTV(nM) 
 
7.09 ±2.84 – 18.25 ±1.72 6.47 ±2.17 
ki DRV (nM) 
 
0.285 ± 0.036 – 3.30 ±1.42 0.49 ±0.20 
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potent PI that can be used in ART.   
The thermodynamics of binding of darunavir to C-SA PR provides insight into the molecular 
mechanism that makes darunavir a stronger-binding protease inhibitor than atazanavir and 
ritonavir. 
5.9  Thermodynamics of binding of atazanavir, ritonavir and darunavir to  
C-SA PR 
The thermodynamics of binding of atazanavir, ritonavir and darunavir to C-SA PR were 
determined in displacement titration calorimetry experiments (Figure 33 and Figure 34). The 
errors of the Kd values are proportionally large, although the standard deviation of the fitted 
data sets were not excessive (Figure 33). It is likely that the Kd errors are large because of the 
standard deviation of the fit across the transition regions of the sigmoidal thermograms of the 
titrations (Figure 33). Slight deviations in the fitted gradient of the transition region can 
reflect as large errors of the Kd, especially since the Kd values are in the picomolar range. 
Moreover, it has been noted that for tight binding systems (Kd in the nanomolar range), data 
fitted with NanoAnalyze (TA Instruments) has produced errors as high as 97% of the Kd 
value (Bechara et al., 2013).  
The binding of atazanavir and ritonavir to C-SA PR is entropically driven and enthalpically 
opposed. This is probably due to the large size of the inhibitors. As seen in Figure 9 A and B, 
the two inhibitors protrude extensively out of the active site of HIV-1 protease, unlike 
darunavir (Figure 8). Indeed, the large molecules would displace a significant amount of 
water molecules contributing positively to the solvent entropy. Thus, the binding of 
atazanavir and ritonavir to C-SA PR is entropically favourable. However, the energy required 
for displacing the water molecules hydrogen-bonded with the protease may not be 
compensated by the energy released by the hydrogen bonds made by the inhibitors with the 
protease. Thus, the enthalpy of binding of atazanavir and ritonavir to C-SA PR is 
unfavourable (Figure 34). Similarly, the binding of ritonavir to C-SA PR was determined to 
be unfavourable by Naicker et al., 2014 (8.37 kJ.mol
-1
), conversely, favourable by Mosebi et 
al., 2008 (-17.57 kJ.mol
-1
). Nevertheless, the enthalpic opposition is not severe. It is possible 
that the enthalpy of the binding of atazanavir and ritonavir to C-SA PR have low enough 
magnitudes to make it difficult to determine whether the binding enthalpy is favourable or 
not. 
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Darunavir fits into the active site of HIV-1 protease without excessively protruding outwards. 
Not surprisingly, darunavir binds to C-SA PR in an entropically and enthalpically favourable 
manner (Figure 34). By far, darunavir has the lowest dissociation constant, in the picomolar 
region. The favourable entropy of binding of darunavir to C-SA PR is most probably caused 
by displacement of water molecules from the active site region of the HIV-1 protease. 
Moreover, it has been elucidated that differences in enthalpic binding between inhibitors is 
due to the packing of water molecules around the PI-PR complex rather than the number and 
location of hydrogen bonds made by PIs with the PR (Mittal et al., 2013). The smaller size of 
darunavir may allow more water molecules to pack around the PI-PR complex. Nonetheless, 
the hydrogen bonding profiles of atazanavir and darunavir are very similar (Mittal et al., 
2013).  
The thermodynamic data for the three inhibitors tested correlates with the determined Ki 
values. That is, the isothermally determined dissociation constant, Kd, is approximately one 
order of magnitude lower than the Ki. That indicates that the fluorogenic substrate used 
competes with the inhibitors, increasing their dissociation constants. 
5.10 Crystallisation of HIV-1 proteases 
Numerous crystallisation trials for C-SA PR and E35D↑G↑S were attempted. Although the 
first crystal structure of HIV-1 protease was obtained from chemically synthesised HIV-1 
protease (Wlodawer et al., 1989), the synthetic E35D↑G↑S sample used in this research did 
not crystallise. Crystal trials require high concentrations of protein. The process of 
crystallisation of proteases is often made challenging due to the inherent autocatalytic 
properties of these enzymes. Although the quantities of proteases available were a limiting 
factor there is a severe lack of structural data regarding C-SA PR and variants of the subtype. 
Therefore, efforts need to be made to produce crystallographic data albeit resource expensive.   
It is recommended that the L33I and L63I autocatalysis-resistant mutations (Mildner et al., 
1994) are introduced in the protease sequences so that the formation of crystals is not as 
limited by autocatalysis. 
6 Conclusion 
The use of lyophilised E35D↑G↑S has revealed that the protease is exceptionally 
autocatalytic, which is problematic for further experimentation. Failure to overexpress 
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E35D↑G↑S as well as the inactive E35D↑G↑S D25A, indicates the codons are incompatible 
with the cells. Codon optimisation of the C-SA PR and E35D↑G↑S protease gene sequences 
is necessary in order to clarify the reasons for the inability of E35D↑G↑S to be 
overexpressed. The experimentally determined kinetic parameters, including those of 
inhibition kinetics, as well as thermodynamic parameters of C-SA PR were determined 
successfully. Darunavir has the advantage of making enough hydrogen bonds (7 hydrogen 
bonds) with HIV-1 protease to bind enthalpically and is small enough to fit in the active site 
without protruding outwards and displacing too many water molecules. Thus, the binding of 
darunavir was established to be entropically favourable. The larger size of atazanavir and 
ritonavir may be the factor that compromises the enthalpically favourable binding of the two 
inhibitors to C-SA PR. 
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CLUSTAL W (1.83) multiple sequence alignment 
 
                Start codon                
C-SA            ATGGACCGTCAGGGTACTGTATCTTTCAACTTCCCGCAGATCACTCTGTGGAAACGTCCG 
E35DGS          ATGGACCGTCAGGSTWYTGTATCTTTCAACTTCCCGCAGATCACTCTGTGGAAACGTCCG 
                ************* *  ******************************************* 
 
C-SA            CTGGTATCCATCAAAGTCGGTGGTCAGATCAAAGAAGCTCTGCTGGACACTGGCGCTGAC 
E35DGS          CTGGTATCCATCAAAGTCGGTGGTCAGATCAAAGAAGCTCTGCTGGACACTGGCGCTGAC 
                ************************************************************ 
                               E35D↑G ↑S  I36L                                                                M46L           
C-SA            GACACTGTTCTGGAAGAA------ATCAATCTGCCGGGTAAATGGAAGCCGAAAATGATC 
E35DGS          GACACTGTTCTGGAAGATGGTAGCTTGAATCTGCCGGGTAAATGGAAGCCGAAATTGATC 
                *****************        * *************************** ***** 
                                                    D60E 
C-SA            GGTGGCATCGGCGGTTTTATCAAAGTTCGTCAGTATGATCAGATCCTGATCGAAATCTGC 
E35DGS          GGTGGCATCGGCGGTTTTATCAAAGTTCGTCAGTATGAACAGATCCTGATCGAAATCTGC 
                ************************************** ********************* 
 
C-SA            GGTAAAAAAGCTATCGGTACCGTTCTGGTTGGTCCGACTCCGGTTAACATCATCGGCCGT 
E35DGS          GGTAAAAAAGCTATCGGTACCGTTCTGGTTGGTCCGACTCCGGTTAACATCATCGGCCGT 
                ************************************************************ 
 
C-SA            AACATGCTGACTCAGCTGGGTTGCACTTTGAACTTCCCGATCTCTCCGATTGAAACTGTT 
E35DGS          AACATGCTGACTCAGCTGGGTTGCACTTTGAACTTCCCGATCTCTCCGATTGAAACTGTT 
                ************************************************************ 
                      Stop codon 
C-SA            CCGGTTTAA 
E35DGS          CCGGTTTAA 
                ********* 
 
S1: Nucleotide sequence alignment of C-SA PR and E35D↑G↑S   
 
Sequence aligned with Clustal W 1.83. Start and start codons are underlined and annotated. 
The mutated codons are underlined. The two insertions are highlighted in grey. 
 
